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Introduction

must recruit healthy volunteers who often are
economically and socially vulnerable and at
substantial risk of HIV infection.
An inherent challenge for the informed
consent process in HIV prevention trials is
ensuring that participants understand that
trial participation will neither protect them
from nor increase their exposure to HIV. Researchers must reinforce the unknown efficacy
of the test product so that participants do not
feel a false sense of protection, or “therapeutic
misconception,” which could lead to
increased risk behavior (such as reducing condom use or increasing numbers of partners).
There is extensive literature concerning
the theoretical considerations of informed
consent and its role in ethical research. Many
studies have been conducted to assess specific
aspects of informed consent, such as comprehension, readability, and presentation of information. However, the majority of these studies involved treatment for people with lifethreatening diseases such as cancer, and few
have been conducted in developing countries.
The practical aspects of informed consent for clinical trials of prevention technologies have received far less attention; only a
few studies have addressed informed consent
in contraceptive and (non-HIV) vaccine trials
(Rivera et al. 1992; Préziosi et al. 1997;
Fortney 1999; Leach et al. 1999). As the
number of HIV prevention trials increases,
several researchers have described the challenges and the importance of implementing
an effective informed consent process, highlighting the need for information on the
practical aspects of effectively implementing
informed consent (Ramjee et al. 2000;
Kilmarx et al. 2001; Coletti et al. 2003;
Mariner 2003).

In the dynamic and rapidly
evolving arena of HIV/AIDS
research, informed consent is recognized
as a critical dimension of making ethics operational. Informed consent has been identified
as a priority area in a wide range of consultations and meetings on ethics and clinical trials, including Practical and Ethical Dilemmas
in the Clinical Testing of Microbicides (Heise
1998); Rethinking the Ethical Roadmap for
Clinical Testing of Microbicides (Global
Campaign for Microbicides 2005); Stakeholder Consultation to Address Issues Related to
Tenofovir Prophylaxis Research (International
AIDS Society 2005); and Creating Effective
Partnerships for HIV Prevention Trials
(UNAIDS 2006). Ensuring informed consent
in clinical trials is a shared goal among
researchers and activists seeking to design and
implement technically and politically complex research in a manner that respects the
priorities and rights of trial participants
and communities.
Although ensuring informed consent and
voluntary participation is one of the most
complicated aspects of conducting any clinical trial, HIV prevention trials, many of
which are being conducted in resource-poor
settings, pose greater ethical and practical
challenges than do other trials. First,
HIV/AIDS remains highly stigmatized in
many of the settings where clinical trials of
prevention technologies are being conducted.
Second, such trials involve other sensitive
issues, including sexuality and gender-based
power dynamics. Finally, because large-scale
efficacy trials must be conducted in areas
with a high incidence of HIV, researchers
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Informed consent is sometimes regarded
by both volunteers and study staff as merely a
bureaucratic requirement for enrollment in
order to comply with legal and regulatory
codes. Informed consent takes place as a oneway communication: a trial volunteer reads a
complicated legal form, and his or her signature or mark on the form symbolizes “consent” to enroll in the trial. It is a one-time
event that is rarely revisited once the form
is signed and filed. Since many researchers,
trial sponsors and communities consider this
approach to be inadequate for achieving
(and maintaining) truly informed consent,
the HIV prevention field has been moving
away from this more legalistic and mechanistic approach centered on the form and
the signature.
An emerging view positions informed
consent as an agreement between the
researcher and the participant that should be
based on dialogue and reinforced through an
ongoing process throughout the trial. A number of HIV prevention trials are investing in
and experimenting with a range of dynamic
and creative approaches to ensuring informed
consent. These include providing one-on-one
counseling and support with well-trained
staff; developing and deploying supplemental
tools such as videos and booklets; systematically assessing comprehension; and actively
engaging communities as partners in the
informed consent process.
A growing number of trials of HIV prevention technologies are underway and in the
planning phases. These trials provide an
opportunity to evaluate and learn from practical experience with informed consent
processes. The rapid growth and evolution of
the field also underscores the importance of

identifying successful approaches to informed
consent in HIV prevention trials that can be
used and adapted more widely.
Recognizing this opportunity and need,
the Population Council and Family Health
International cohosted an international workshop on 16–18 May 2005, focusing specifically on the informed consent process in HIV
prevention trials. To facilitate learning among
participants with diverse backgrounds and
approaches, the meeting blended experience
from ongoing and planned clinical trials with
theoretical underpinnings in areas like risk perception, adult learning theory, and bioethics.
The workshop drew together more than 70
participants from 11 countries and varied
backgrounds: representatives from research
institutions, trial sponsors and advocacy
groups; donors; principal investigators and
clinic staff; social scientists; and experts in
related fields. A third day was targeted to a
subset of participants directly involved with
developing materials and implementing the
informed consent process. (See Table 1 on page
4 for a complete list of the trials represented.)
Workshop participants enjoyed a rich
and lively set of presentations and discussions
on key practical and conceptual issues concerning informed consent. Many participants
shared their experiences with the dynamic
and sometimes frustrating processes of developing materials, designing and implementing
new procedures, conducting assessments, and
advocating for the importance of attention to
informed consent within complex trial and
community contexts.
This report captures the main topics discussed at the workshop. The first section
reviews the historical and regulatory foundations of informed consent. The next section
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touches on several among myriad factors that
influence informed consent: contextual
issues; risk perception and decisionmaking;
compensation; and autonomy, especially with
regard to women’s participation in clinical trials. A related discussion follows concerning
the central role that communities can play in
informing research processes as well as influencing individual decisions. The main section
of the report explores a range of practical
issues related to developing and using tools to
enhance the informed consent process and is
followed by a discussion of how best to assess
the effect that all these efforts have on participants’ comprehension. These sections, in
particular, incorporate examples from completed and existing clinical trials to illustrate
concrete opportunities and challenges associ-

ated with this process. The final section
reviews results and strategies for evaluating
informed consent processes. The report ends
with recommendations for further consultation and research on this issue.
The workshop underscored the dynamic
and creative way that clinical trial sponsors
and investigators, clinic staff, social science
researchers, donors, and communities are
approaching the challenge of informed consent in these complex and critical trials.
Participants left the workshop charged with
new ideas and approaches to bring to their
work and committed to identifying opportunities for ongoing collaboration. Addressing
these compelling issues is central to the ethical and practical implementation of this critically important research.
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Table 1 Trials represented at the workshop on informed consent in HIV prevention trials, 16–18 May 2006
Product
Trial descriptiona
BARRIER METHOD
Latex diaphragm
Latex diaphragm to prevent HIV
acquisition among women/
“female-controlled” physical
barrier of the cervix (“Methods
for Improving Reproductive
Health in Africa/MIRA”)
MICROBICIDES
TM
Phase 1 safety and acceptability
BufferGel
(HIVNET 009)
study in low-risk women

BufferGelTM and
PRO 2000
(HPTN 035)

Phase 2/2b safety and
effectiveness study

Carraguard®

Phase 3 safety and efficacy trial
to prevent HIV seroconversion
in women
Phase 1 safety and acceptability
study in HIV-negative, monogamous, low-risk couples (TUC)

Carraguard®

Cellulose sulfate/
CS (6%)
PRO 2000
(HPTN 047)
PRO 2000

Phase 3 randomized controlled
trial for safety and efficacy
Phase 1 safety and acceptability
study
Phase 3 trial to determine
efficacy and safety of two
concentrations (0.5% and 2%)
of PRO 2000

SavvyTM (C31G)
(1.0%)
Tenofovir gel (1%)
(HPTN 055)

Phase 3 randomized controlled
study of safety and efficacy
Phase 2 safety and acceptability
study, comparing daily and
coitally dependent use

Developer/sponsorb

Sites

Janssen Ortho MacNeil
Pharmaceuticals/University
of California at San Francisco/
Bill & Melinda Gates
Foundation

Durban and Johannesburg,
South Africa
Harare, Zimbabwe

ReProtect/Family Health International (FHI)/Fred Hutchinson
Cancer Research Center/
National Institute of Allergy and
Infectious Diseases (NIAID)
Indevus/ReProtect/NIAID

Pune, India
Chiang Mai, Thailand
Blantyre, Malawi
Harare, Zimbabwe

Population Council/USAID/
Bill & Melinda Gates
Foundation
Population Council/US CDCThai Ministry of Health
Collaboration/Bill & Melinda
Gates Foundation
CONRAD/Polydex/Family Health
International (FHI)/USAID
Indevus/NIAID
Indevus/Microbicides Development Project (UK Medical
Research Council and DFID)
Biosyn/Cellegy/ Family Health
International (FHI)/USAID
Gilead/NIAID

Blantyre and Lilongwe, Malawi
Hlabisa and Durban, South Africa
Philadelphia, United States
Lusaka, Zambia
Chitungwiza and Harare, Zimbabwe
Cape Town, Durban, and
Pretoria, South Africa
Chiang Rai, Thailand

Benin; Burkina Faso;
India; South Africa; Uganda
Pune, India
Durban, Johannesburg, and
Mtubatuba, South Africa
Mwanza, Tanzania
Masaka, Uganda
Mazabuka, Zimbabwe
Accra and Kumasi, Ghana
Ibadan and Lagos, Nigeria
Pune, India
Birmingham, Alabama, and New
York City, New York, United States

PILL FOR PRE- (HIV) EXPOSURE PROPHYLAXIS (PREP)
Tenofovir

Phase 2 safety and effectiveness
trial in high-risk men and women

Tenofovir

Phase 2/3 trial assessing safety
and efficacy of daily prophylaxis
in reducing HIV transmission
among young adults

Gilead/Family Health International/Bill & Melinda Gates
Foundation
Gilead/CDC

Douala, Cameroon
Tema, Ghana
Ibadan, Nigeria
Francistown and Gaborone,
Botswana

PILL FOR TREATMENT OF HERPES SIMPLEX-2 VIRUS
Acyclovir

Phase 3 trial of acyclovir for
HSV-2 suppression among HIVdiscordant couples

University of Washington/Bill
& Melinda Gates Foundation

Gaborone, Botswana
Nairobi, Kisumu, and Eldoret, Kenya
Kigali, Rwanda
Cape Town and Johannesburg,
South Africa
Moshi, Tanzania
Kampala, Uganda
Lusaka and Ndola/Kitwe, Zambia

Phase 3 efficacy trial among
injecting drug users

VaxGen/Thai Ministry of Public
Health and US CDC

Bangkok, Thailand

HIV VACCINE
Bivalent B/E rgp
20 HIV vaccine

Note: Adapted from Friedland (2005).
a
Unless indicated otherwise, the objective of the trial is reduction in HIV transmission.
b
The term “sponsor” is used here as defined by the International Conference on Harmonisation (Guideline for Good Clinical Practice 1996: p. 7) as follows: “An individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial.”
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Setting the Stage
Informed consent is a central
tenet of research ethics reflected
in documents and guidelines

tion (ICH), the US Food and Drug Administration (FDA), and the US Office of Human
Research Protections (OHRP). These regulations lay out the broad areas that must be
addressed in informed consent documents
(for example, see box on page 6: Basic Elements of Informed Consent). These guidelines, in varying specific terms, indicate that
the principal investigator is responsible for
providing information in a manner that is
understandable to the research participant
and that the prospective participant should
be given sufficient time to consider whether
to participate or not. All guidelines and regulations include requirements for documentation of the consent process, whether or not
the study participant can read and/or write.
However, these regulations offer little
guidance on specific approaches to use to
ensure informed consent—how information
should be presented or what tools should be
used for doing so. ICH guidelines suggest
that the principal investigator is responsible
for ensuring that “information in the consent
form and any other written information was
accurately explained to and apparently understood by the subject . . .” (ICH 1996: 16),
but they offer no specific guidance or standards for assessing this “explanation” or
“understanding.” Similarly, the United States
Code of Federal Regulations, which applies
to studies conducted under the auspices of
the US FDA, states that “the information
that is given to the subject or the representative shall be in a language understandable to
the subject,” but includes nothing about
researchers’ responsibilities for ensuring study
participants’ comprehension (OFR 2002).

dating back to the Nuremberg Code
(NCPHSBBR 1949), through the
Declaration of Helsinki (1964) and its revisions, the Belmont Report (1979), the
Council of Europe (1997), and the Nuffield
Council on Bioethics Guidelines (2002).
Although definitions vary and the specifics
of implementation have evolved somewhat
over time, informed consent is based on
three main premises: disclosure—providing
information, appreciation—participant’s
understanding, and voluntariness—the ability to enroll in a trial and to leave it voluntarily (Singh 2005).

Basic Ethical Principles in the
Belmont Report
Respect for Persons: Individuals should
be treated as autonomous agents, and
persons with diminished autonomy are
entitled to protection.
Beneficence: Possible benefits of
research should be maximized and possible harms minimized.
Justice: Those who realize the benefits
of research should share in its burdens,
and those who share in its burdens
should also realize the benefits.

A number of national and international
bodies provide regulations and guidance on
the conduct of informed consent, including
the International Committee on Harmonisa-

5

IPD.INFORMEDCONSENT.2006

3/28/06

1:31 PM

Page 6

Existing literature and the experience of
meeting participants suggest that clinical trial
participants often have difficulty understanding the information presented in informed
consent materials. When informed consent
forms present comprehensive information
about a trial—either to provide the trial volunteer with all relevant information or to
provide legal protection for the trial—trying
to understand them can be overwhelming for
the trial volunteer. These forms—sometimes
more than ten pages of dense, single-spaced
text—are visually complex and often include
highly technical language. Translation can
make technical terms and concepts even more
difficult to understand. These challenges are
exacerbated in settings of low literacy, where
potential research participants may have little
understanding of disease processes or
research, and where local languages may lack
terms for key research concepts.

Basic Elements of Informed Consent—
US Code of Federal Regulations: 45
CFR 46.16
In seeking informed consent, the following information shall be provided to each subject:
1. A statement that the study involves research,
an explanation of the purposes of the
research and the expected duration of the
subject’s participation, a description of the
procedures to be followed, and identification
of any procedures which are experimental;
2. A description of any reasonably foreseeable
risks or discomforts to the subject;
3. A description of any benefits to the subject or
to others which may reasonably be expected
from the research;
4. A disclosure of appropriate alternative procedures or courses of treatment, if any, that
might be advantageous to the subject;
5. A statement describing the extent, if any, to
which confidentiality of records identifying the
subject will be maintained;

In practice, some of the regulations
designed to protect research participants may
undermine the informed consent process,
albeit unintentionally. For example, in some
settings, any signed paper is perceived as a
formal contract—“like signing a bank check”
—so a signature on an informed consent
form may connote a binding obligation
(Pennington 2005). Participants may feel
unable to break such an agreement even if
they wish to withdraw from the trial and
have been told that they have the right to do
so. In such a setting, requiring a trial participant to sign an informed consent form may
contradict the concept of voluntarism and
the right to withdraw. It may also create a
barrier to participation if concerns about the
meaning of a signature outweigh the desire
to participate.

6. For research involving more than minimal risk,
an explanation as to whether any compensation and an explanation as to whether any
medical treatments are available if injury
occurs and, if so, what they consist of, or
where further information may be obtained;
7. An explanation of whom to contact for
answers to pertinent questions about the
research and research subjects’ rights, and
whom to contact in the event of a researchrelated injury to the subject; and
8. A statement that participation is voluntary,
refusal to participate will involve no penalty or
loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without
penalty or loss of benefits to which the subject is otherwise entitled.
Source: Office of the Federal Register (2002).
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In the absence of consistent regulations
and guidance, informed consent documents
and processes can be influenced heavily by
ethics committees or institutional review
boards (IRBs). IRBs play a critical role in
providing ethical oversight and protecting
research participants. In practice, however,
the current IRB system can vary considerably
among different institutions and, in certain
settings, can operate with little standardization, transparency, or accountability. An
IRB’s capacity to review appropriately a
diverse range of clinical and related behavioral research can be strained in any institutional setting. These limitations can be of
particular concern in the context of large
international and multisite trials when IRB
members may have little or no familiarity
with the trial setting.
Collaborative trials with multiple IRB
reviews often face reconciling sometimes
competing and contradictory requirements

and recommendations regarding informed
consent approaches, forms, and supplementary materials. For example, a situation arose
in which a US-based IRB required that a
study’s informed consent form contain language describing possible DNA testing and
disclosure of paternity status. Because no
DNA testing was being performed at one of
the non-US collaborating study sites, its IRB
felt the language regarding DNA testing
should be deleted from the form. The USbased IRB, however, insisted that its legal
department required that this language be
included on all consent forms for studies and
sites for which they have oversight
(Pennington 2005). Workshop participants
noted that the ethical safeguards provided by
IRBs, although critical, in practice can hinder
the development and implementation of
informed consent processes that are appropriate and responsive to a range of trial participants and settings.
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Factors Influencing Informed Consent
broader legal, political, and economic arena
that has global as well as local dimensions.
Factors external to the trial and the local community can affect perceptions of a trial and
individual decisions about trial participation.
For example, a study of willingness to participate in an HIV vaccine trial documented a
significant decline in willingness at one of the
trial sites. This decline followed a misleading
headline in a local newspaper indicating that
the vaccine had “failed” to prove protective in
a Phase 2 trial (a trial that was not, in fact,
measuring effectiveness) (Bartholow et al.
1997). Trial participants exist within a complex web of relationships that may have a
strong influence on their perceptions and
actions related to issues of trial “ethics.” In
HIV prevention research, this situation can
be exacerbated by stigma, judgment, and fear.
Participants’ perceptions or experience with
authority may make them feel unable to leave
a trial even if they are assured repeatedly that
they have a right to do so. Evaluation of an
informed consent process among women
attending an antenatal clinic who were
recruited for a perinatal HIV-transmission
study showed that although they responded
“yes” when asked if they understood that they
were free to leave the study at any time,
almost none of the participants believed that
the hospital would allow them to quit the
study. One-fourth to one-third of the respondents thought that their care would be compromised if they left the study (Abdool
Karim 1998).
Although a particular trial may work to
support and respect the dignity and rights of
participants, most populations at risk of HIV

Informed consent is premised
on the notion that individuals
have the right and the ability to
make decisions in their own
interest and to act upon them.
In reality, the ability to make decisions, as
well as the decisions themselves, are often
constrained by a range of factors. For example, in many settings, important decisions are
not made by individuals. A decision may be
influenced or made by a family member,
family group, employer, or the community,
more broadly, which is particularly true for
many women in settings where decisions are
traditionally made by men. Women may not
have the autonomy or the legal right to make
the kinds of decisions encompassed by
informed consent. Issues of autonomy and
decisionmaking can be especially complex for
HIV prevention trials that are enrolling
healthy people, and can raise highly charged
issues concerning sex, trust, gender and
power. Finally, it is important to recognize
that decisionmaking is characterized by the
complexity and contradictions inherent in
human nature and human behavior.
The workshop highlighted broad contextual considerations as well as specific issues
that influence decisionmaking regarding consent to participate in a clinical trial: risk perception; remuneration; community influence;
and the use of informed consent advocates.

Informed Consent in Context
HIV prevention trials take place within a
complex and layered series of contexts: the
trial itself, the social setting of the local community where the trial takes place, and the

8

IPD.INFORMEDCONSENT.2006

3/28/06

1:31 PM

Page 9

both dimensions of risk: its magnitude and
the likelihood of its occurrence.
Myriad background factors, including
ethnicity, socioeconomic status, and sense of
agency, can also influence how individuals
assess risk and the actions they take as a result.
An essential corollary to risk assessment is
whether individuals or communities trust the
source of information to represent the risk
accurately. This trust is influenced by whether
an individual or group has had a history of
positive or negative experiences with the health
system, with law enforcement, with research
institutions, or with government. In the generally resource-poor settings where HIV prevention trials are being conducted, it is critically
important to recognize the historical backdrop
of colonialism and racism, and ongoing challenges of poverty and exploitation. In this
light, building and maintaining trust among
researchers, communities, and participants can
be a critical element of informed consent.

are marginalized and vulnerable because of factors such as gender, sexual orientation, poverty,
education, use of injecting drugs, or sex work.
Clearly, trials must not exploit or intensify this
vulnerability, yet neither can they redress the
broader social, economic, political, and legal
factors that condition it. It can be difficult to
anticipate participant and community perceptions of many trial ethical obligations and
decisions. For example, benefits offered as part
of a researcher’s ethical obligation or to
enhance participants’ benefits, such as antiretrovirals or other medical care, may be perceived as unfairly and inappropriately creating
an inequity within a family.

Risk Perception and Decisionmaking
Weighing potential risks and benefits is crucial to fully informed consent, and the field of
risk perception offers a number of insights for
prevention research. In communication campaigns as well as research settings, “risk” tends
to be presented in terms of quantitative estimates that emphasize the probabilities of particular outcomes. Research on risk perception
suggests that people of all educational backgrounds generally find applying such quantitative estimates to actual decisions and actions
difficult (Downs 2005). Therefore, when risks
must be “quantified,” people may better comprehend broader concepts that allow comparison among “high” and “low” risk, rather than
comparison among specific percentages or
numeric estimates. Generally, a more qualitative presentation and understanding of risk is
likely to be more relevant to people’s decisionmaking. The presentation should capture

Impact of Participant Remuneration
on Informed Consent
Compensation is widely recognized as a critically important factor influencing voluntariness of trial participation. However, regulations and guidelines for informed consent are
vague about where the distinctions can reasonably be drawn between “fair compensation” and
“undue inducement.” This vagueness is particularly problematic in resource-depleted settings
and in multicenter trials. In reality, an “inducement” of some kind is inherent in every research endeavor, and most trials provide participants with money, health care, or other benefits.*

* The complexity of this issue is exemplified by the way in which language is used. Although many associated terms
(such as “compensation,” “remuneration,” “reimbursement,” and “benefit”) have specific technical definitions, they
can be used imprecisely and interchangeably. Capturing the precise meaning of these terms is further complicated
by translation in many trials.
9
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Three general models have been proposed for determining appropriate payment
for research participants (Dickert and Grady
1999). The “market model” suggests payment
according to “market forces” such as the levels
of risk and benefit, scarcity of potential participants, and the arduousness of the protocol. This model is generally rejected as unacceptable because high payment could too easily overshadow an appropriate assessment of
risks. In the “reimbursement model,” participants receive payment for expenses and, in
some cases, for missed wages that are directly
related to study participation, without taking
into consideration effort or discomfort. A key
drawback of this model is that each participant will receive a different amount of money.
The “wage-payment model” equates research
participation with unskilled labor and standardizes the “wage” associated with trial participation. A potential problem with this
model is the commercialization of trial participation, which might also warrant the inclusion of typical employment benefits, such as
insurance and comprehensive health care. Although these models are useful, each has
shortcomings in implementation. Determining which model might be the most appropriate in a particular setting is essential. Further
research is needed in order to better understand the impact of remuneration on informed consent and voluntary participation.
Controversy around the issue of balancing
compensation with inducement was played
out recently in South Africa when the Medicines Control Council (MCC) mandated a
reimbursement of 150 Rand (US$25) per visit

for all clinical trials. This amount reflected the
MCC’s desire to make remuneration fair and
equitable for study participants across trials,
settings, and economic status. Some research
ethics committees, however, questioned
whether this payment represented excessive
remuneration, becoming an “undue inducement” for people from the poor, often vulnerable communities where HIV/AIDS research
generally is conducted (Moodley 2005).
Several recommendations were offered
for addressing this ongoing controversy:
empower ethics committees to guide remuneration decisions; determine remuneration
on a case-by-case basis with, perhaps, a common minimum amount; examine the effect
of the timing of disclosure of remuneration
on the decision to enroll in a trial; and base
decisions about remuneration on empirical
research among ethics committees, investigators, and participants. A suggestion was made
at the workshop that in addition to providing
benefits to individuals who participate in the
trials, research communities might also be
provided with benefits such as post-trial
access to products that are proved effective.*

Defining the Trial “Participant(s)”
HIV prevention trials can pose a number of
challenges regarding autonomy and disclosure
for trial participants, particularly trials that
enroll women. For example, in many settings,
microbicide and diaphragm trials that enroll
women grapple with how and how much to
involve men in decisionmaking and in the trial
itself. Other trials, such as certain microbicidesafety studies and an efficacy trial of acyclovir

* The “fair benefits” model explores this and other types of benefits that could be negotiated among
researchers, sponsors, and host-country stakeholders. For more information, see Participants in the 2001
Conference on Ethical Aspects of Research in Developing Countries (2002).
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for suppression of herpes simplex virus (HSV2), are enrolling couples. Presentations and
discussions at the workshop highlighted a
number of models for addressing sexual partnership issues in prevention trials:

pants may have complex partnership arrangements that they do not wish to acknowledge,
including multiple partners, extramarital partners, casual partners, or commercial sex partners. Although there was no clear consensus
on how to address this issue, workshop participants acknowledged that the best approach
should respond to practical considerations
while not compromising women’s autonomy.
One strategy being used by a number of studies to balance these competing concerns is to
provide general information to the community and to support women who wish to inform
or involve their partners, relying on the
woman’s suggestion and discretion. A variety
of approaches can be used, such as development of informative materials, male partner
information sessions, or couples counseling.
Researchers seeking to enroll couples into
trials also face difficult issues related to informed consent, as illustrated by two examples
presented at the workshop. The first is a Phase
3 randomized controlled trial of acyclovir for
suppression of HSV-2 to prevent HIV transmission among HIV-discordant couples, being
conducted by the University of Washington’s
Partners in Prevention. The hypothesis is that
suppression of HSV-2 in HIV-positive partners using acyclovir twice a day for a year will
reduce transmission to the HIV-negative
partner by half. (Mujugira 2005). More than
3,600 couples will be enrolled at sites in six
African countries and in India.
The recruitment strategy is based on couples’ voluntary counseling and testing (VCT).
Research staff have invested considerable resources in retraining VCT counselors to work
with couples rather than with individuals. To
address people’s concerns about testing positive
and informing a partner, couples are encour-

• community outreach and provision of
information to men to ensure community support for the study;
• counseling and informing trial participants’ husbands or partners only at the
participant’s request;
• requiring formal consent from partners
for women to enroll in a study;
• considering sexual partners as “participants” whose consent is required if they
are likely to be exposed to the experimental product (such as a microbicide); and
• enrolling both partners as trial participants in couples studies.
Questions about the appropriate role for
men in studies that enroll women touch on
issues of autonomy, transparency, confidentiality, and local cultural norms that govern
gender relations. As a practical matter, involving men, up to and including requiring
formal partner consent, may be seen as necessary for respecting cultural norms, ensuring
community support and transparency, and
allaying suspicion and rumor. Paradoxically,
in studies testing female-initiated methods
like microbicides and diaphragms that are
designed to give women more autonomy
and control, requiring partner consent will
compromise the trial participant’s autonomy
and confidentiality, critical elements of
research ethics.
In large-scale studies enrolling diverse
populations, obtaining consent from partners
may not be feasible. For example, trial partici-
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aged to be tested and find out their HIV status
together. Because both partners must understand the overall concept of the study, it is explained to them jointly. However, some of the
study procedures differ for the HIV-positive
partner and the HIV-negative partner, so the
consent process and forms also differ. A more
serious concern is the potential for coercion,
exacerbated by the gender power imbalances
that generally leave the man as the final decisionmaker. To address concerns around providing clear information and ensuring that women
are not coerced to join the study, the consent
is administered separately to the partners.
A second study involved 55 HIV-negative,
low-risk couples in a Phase 1 safety study of
the candidate microbicide Carraguard® (Chaikummao 2005). Researchers in Chiang Rai,
Thailand, found it challenging to engage men,
because they were less concerned about their
own risk behavior or health-related issues than
were their wives or partners. Many men faced
constraints in coming to the clinic because of
work commitments. The study team found that
only couples with good relationships were likely to enroll and that even so, participants were
concerned about disclosing their test results to
their partners. Participation in the couples
study also had benefits, including improved
communication between partners about sexual pleasure, risk, and HIV prevention.

those who may be illiterate, understand the
study at the time of consent. An independent
witness, employed under a contract separate
from that of the trial, observes the consent
process to verify that the consent form is
reviewed in full, that the potential participant’s questions have been addressed satisfactorily, and to look for any indication that the
participant may not fully comprehend the
information provided prior to signing the consent form. If the advocate perceives a problem
with regard to comprehension, and the problem cannot be satisfactorily resolved, the advocate has the authority to determine that the
person is ineligible to participate in the trial,
just as research staff conducting the informed
consent process would be able to do.
A number of workshop participants
raised concerns about whether such a mechanism—which may be perceived as delegating
decisionmaking to a third party—compromises the trial volunteer’s autonomy. Further
discussion indicated that use of the term
“advocate” may imply a more active role than
was the case in this instance and that “witness” might be a better description.
In general, workshop participants felt
that the strategy represented an innovative
effort to preserve participant confidentiality
while responding to the regulatory requirement to provide an independent witness for
illiterate participants. Given the complexity
of issues and participants’ needs that are likely to emerge in large-scale HIV prevention
trials, and the lack of experience to draw on,
it is important for staff, communities, and
researchers to feel empowered to experiment
with new and creative approaches to respond
to participants’ needs.

The Informed Consent Advocate
In its microbicide and pre-exposure prophylactic (PREP) trials, FHI has been experimenting with employing an “advocate” to help
ensure informed consent (Attafuah 2005).
This innovative effort provides additional support to ensure that trial volunteers, especially
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Community Involvement and Informed Consent
The extent to which community
engagement infuses the informed
consent process was striking
throughout many workshop
presentations and discussions;

ual’s evolving perceptions of the study (Woodsong and Karim 2005). This model acknowledges that the community’s perceptions and
experiences will influence individual decisions
about trial participation and that individuals’
experience, in turn, will help shape community perceptions and support for others to enroll
in the study. Informed consent is embedded
in an overall process of community consultation and involvement aimed at preparing the
community for research and the research for
the community. Similar approaches are being
taken by a number of other trials represented
at the workshop.
An ongoing challenge in community participation is defining the “community.” In
relation to research participation, it can be
defined as the group of people likely to be
affected by, or have an influence on, the
decision of participants to join the research.
Family, friends, and peers; local administration; and local groups such as churches,
clubs, and youth and advocacy groups can
have varying degrees of influence. Most
workshop participants recommended defining the community broadly to engage a wide
array of stakeholders: potential trial volunteers, community leaders and activists, members of the ethical review committee, and
national and even international civil society.
Such a broad definition of community poses
challenges, however, including how to preserve participants’ confidentiality as well as
how much information should be presented
to which constituencies at which point in the
process.

working with communities is an integral part
of the informed consent process in many
HIV prevention trials. Communities play a
variety of roles in the informed consent
process: they formulate approaches to information provision; help to develop, review,
and test materials; and alert researchers to
emerging community concerns. Many of
the trials represented at the workshop
consider community outreach and involvement to be an important first step in
informed consent. In most settings, community outreach and involvement was linked to
the informed consent process whether formally or informally.
The HIV Prevention Trials Network
(HPTN) 035 trial provided a useful case
study of approaches to developing an
informed consent process that can be implemented consistently across multiple sites in
diverse cultural settings. HPTN 035 is a fourarm randomized Phase 2/2b trial of two candidate microbicides and two control arms that
will enroll 3,220 women in five countries.
The HPTN informed consent process is built
on a conceptual model that recognizes the
links between the community and the individual and the interrelationships among the
community’s introduction to the study, the
administration of informed consent to the
individual, and the community’s and individ-
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tings, anything related to HIV, including a
prevention trial, could stigmatize participants.
Based on rich experience, there is an ongoing and evolving debate about—and experimentation with—how community involvement in clinical trials can best be facilitated.
The most common approach has been to
establish structures such as a committee or
board specifically for soliciting input or advice
from the community. Often referred to as
community advisory boards (CABs),* they
have played a pivotal constructive role in many
settings by fostering dialogue, developing common understanding, reviewing protocols and
research approaches, and building trust. It is
important to cultivate and train a cadre of people to answer questions accurately and openly
on topics about which people may be reluctant
to ask study staff directly. Community advisory
boards can help to reinforce key concepts such
as voluntarism and aid in the appropriate
assessment of risks and benefits. With regard to
informed consent, the community advisory
board and other community structures can
assist with developing language, terms, and
analogies to convey research concepts.
Some participants noted that CABs also
have limitations. They may not represent
community views or interests, and they can
become entrenched or “colonized” by the
trial. It can be especially difficult for marginalized groups such as injecting drug users and
sex workers or, in some settings, women and
young people, to be heard and represented
through such formal structures. CABs may
also need training in research methods and

Another approach to defining community is to ask people who are likely to be recruited for a trial to describe what communities or
other important social groups they belong to
or identify with and who they feel can best
represent their interests. Social science
research methods can be used to describe the
diversity and cohesiveness of these participant
stakeholder communities. This information
can help guide decisionmaking about how to
build effective partnerships with communities
and ensure that spokespersons can represent
fairly community and research participants’
concerns (Weijer and Emanuel 2000;
MacQueen et al. 2001).
Some studies use a detailed recruitment
session that also serves as a way to inform
community members about the trial. A number of workshop participants argued that all
information about the study should be introduced and explained during outreach visits.
Others maintained that this approach was too
burdensome for the participants and the research staff and that more general information should be provided together with contact information so that people who are interested and want additional information can
follow up.
A related concern is balancing the need
and desire for transparency with the necessity
of maintaining confidentiality and the possibility of stigmatizing potential trial participants. In HIV prevention trials, where testing
positive is an exclusionary factor, potential
trial participants who screen out of a trial may
be assumed to be HIV-positive. In some set-

* Studies represented at the workshop referred to these structures as community advisory boards (CABs) or community advisory groups (CAGs). The two terms are used interchangeably in this report.
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Centers for Disease Control and Prevention.
Prior formative research underscored the importance of informing participants, partners,
and the community through a consultative
process that, in turn, informs the researchers.
The trial team sought the opinions of a
diverse range of partners among researchers,
participants, and the community using a variety of mechanisms including advisory groups,
community meetings, and individual interviews. In addition to community advisory
groups in each site, the trial uses participant
advisory groups and consults regularly with a
range of other community stakeholders. The
study employs two full-time community liaison officers who are well trained and connected in the community and who work
closely with local and national ethics committees. Formal rapid assessments conducted
every six months provide an opportunity to
monitor what is being said in the community. These assessments also help address questions and concerns, clarify issues, and dispel
myths and rumors that emerge.
A presentation from the HPTN 035
study site in Zimbabwe highlighted many of
the issues related to community involvement
in informed consent, and in trials more
broadly, that came up throughout the meeting (Chigwanda 2005). Community involvement in decisionmaking is embedded in the
cultural tradition of Zimbabwe, in which the
participant is a member of a variety of social
groups and responsive to a range of social
influences. A significant number of people
rely on natural support systems such as families, friends, clubs, church, or other organizations—rather than on professional or formal
groups—when weighing a decision about

ethics to help members better understand
research concepts and ensure that they will
respect the confidentiality of those who seek
their advice (Rivera et al. 2004). Multiple
strategies are needed to hear diverse voices,
and new approaches are being explored that
could supplement CABs (Hantman and
Gottemoeller 2004).
Several workshop participants cautioned
that it is critically important to define the roles
that researchers and community members
will play in any partnership. Articulating advisory, information-giving, and decisionmaking roles clearly is especially important in light
of growing demands for communities’ involvement in setting priorities, developing protocols,
and designing research—not just in implementing trials. Given the increasing emphasis
placed on community consultation, one participant questioned why more community
members were not at the workshop. Organizers noted that a researcher–community dialogue about informed consent was beyond the
scope of this meeting, but recommended such
a dialogue as a follow-up action. Much of
what was presented at the workshop had, in
fact, grown out of dialogue among researchers
and community members at trial sites.
A broad definition of “community” has
also been adopted for the Botswana Oral
Tenofovir Prophylaxis Trial, a study to evaluate the safety and efficacy of daily oral tenofovir pre-exposure prophylaxis in reducing
heterosexual HIV transmission among young
women and men aged 18–29 (Chillag 2005).
This randomized, double-blind, placebocontrolled trial is being conducted by the
BOTUSA Project—a collaboration of the
Botswana Ministry of Health and the US
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CAB that has played an important advisory
role in developing and testing key messages
and materials for informed consent. Implicit
in these strategies is consulting widely and
listening to community concerns, ideas, and
priorities, as well as providing information.

participating in a trial. In this setting, mobilizing the community included consulting
with relevant structures in the community,
recruiting advisors and opinion leaders, and
raising awareness through informational
meetings and materials. The trial site has a
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Tools to Enhance the Informed Consent Process
Recognizing the limitations of
standard informed consent forms,
investigators and trial staff are
experimenting with a range of
additional tools and processes to
enhance informed consent.

communication and education materials,
because few clinical trial teams include such
experts. Developing these materials also
requires an extensive understanding of the
trial protocol and of the setting. In most settings, study staff, community advisory board
members, participants from earlier trial phases, and potential participants are engaged in
generating ideas, developing approaches, and
pretesting and reviewing materials.
Multicenter trials generally require translation into multiple languages and design
modifications to ensure that the visual depiction of people, settings, and concepts resonates with diverse communities and participants. The meaning of certain drawings or
color choices may differ among settings.
Some trials have developed an overall template for design and information that is completed with details tailored to each setting.
Incorporating protocol changes and responding to questions or unanticipated issues that
emerge in the course of the trial can pose particular challenges, especially when producing
materials such as booklets or videos that
require a long lead time to create and that
must be printed or reproduced. Some trial
teams have addressed this problem by creating more flexible fact sheets or frequently
asked questions (FAQs) to target specific
groups (such as male partners of women in
microbicide trials) or topics (such as HIV
testing), because they are less complicated to

Workshop participants shared and discussed a
number of thoughtful and innovative strategies, materials, and ideas for conveying difficult concepts. Tools that are being developed
and used include study booklets, pamphlets,
fact sheets, radio and newspaper advertisements, videos, audio computer-assisted selfinstruction (ACASI)*, and flip charts. Some
trials also use other visual aids, such as blood
vials, speculae, product boxes, and randomization envelopes, to illustrate particular trial
procedures. Many of the trials use these materials in combinations that build on and reinforce each other to present relevant information to the community, volunteers, and participants throughout the process of a trial by
means of community outreach, information
sessions, recruitment, screening, enrollment,
and follow-up visits.
These materials and approaches have
been developed through careful formative
research, drafting, pretesting, and adaptation,
and are being employed in clinical trials in a
variety of settings. Workshop participants
underscored the complexity of developing
such materials and the importance of engaging professionals with expertise in developing

* In this context, ACASI is used to refer to audio computer-assisted self-“instruction” rather than self“interview,” as it is more commonly known. In the BOTUSA Project trial site, the technology is used to
provide information to volunteers and participants rather than as an interview technique for eliciting
responses on sensitive topics.
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produce and can be adapted relatively easily
and inexpensively.
Workshop participants acknowledged
that developing and using informed consent
tools for HIV prevention trials is still a relatively new area. Little evidence exists concerning whether and how the time and effort
invested in developing and employing these
materials enhances participants’ understanding of trial concepts or their adherence to
study procedures. This section of the workshop report explores a range of issues related
to developing, adapting, and using materials
designed to enhance the informed consent
process: formative research; developing and
using specific tools; targeting trial information and tools for specific audiences; explaining difficult concepts; and training staff.

a community’s knowledge of and preconceptions about health and the research process,
concepts that may be difficult to explain. It
may also suggest creative and accessible ways
to explain these concepts.
HIV prevention trials have used a variety
of approaches to formative research with
varying degrees of formality from community
meetings to interviews or focus-group discussions with key informants, community leaders, potential trial participants, other community members, and the health professionals
who serve them. A number of key issues have
emerged from this process.
The BOTUSA Project’s PREP trial, for
example, included an extensive process of
formative research and community preparedness that led the project team to be concerned about therapeutic misconception (that
people would mistakenly think that the test
products and/or placebo were known to be
effective) and about behavioral disinhibition
(participants’ neglect of risk-reduction practices based on their belief that the test product and/or placebo is effective). The findings
also underscored the importance of transparency (including educating the community,
participants, and partners) and of communities’ high levels of hope for new HIV prevention interventions in the face of the epidemic.
These findings influenced the design of the
trial’s community consultation process (see
section above on community involvement
and informed consent). As a result of the
findings, all educational and informed consent documents and processes explicitly reinforce the experimental nature of the trial. At
the time of the workshop, participant enrollment had not yet begun, so the effectiveness
of these measures is not yet known.

Formative Research
Formative research is critical for identifying
and developing clinical trial sites and for
informing specific approaches to protocol
design and implementation. Often it is conducted concurrently with site-preparedness
activities and can also present opportunities
to establish initial contact with community
leaders and members. Formative research can
be used to assess general questions critical to
the trial, such as a community’s perceptions
and openness to the research, potential participants’ background knowledge of
HIV/AIDS and related health and social
issues, and approaches to structuring community participation. It can also inform practical
decisions related to trial implementation,
such as where to locate clinics and recruitment sites to maximize participants’ convenience and to protect their privacy. Finally, this
initial research is also crucial for determining
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To inform approaches for the Phase 3
efficacy trial of Carraguard being implemented at three sites in South Africa, the Population Council conducted focus-group discussions and in-depth interviews with trial participants and study staff at two of the study
sites that had been involved in an earlier
Phase 2 safety study (De Kock et al. 2005).
This research assessed comprehension of the
trial’s purpose and procedures, identified
ways to explain difficult concepts, and solicited recommendations for recruitment and
informed consent processes for the Phase 3
trial. Phase 2 participants recommended
strongly that the study team develop a video
to present basic trial information and explain
difficult concepts; they felt that a video
would be more engaging and informative
than print material or presentations by study
staff, especially for recruitment.
Based on this formative research, the
Population Council developed a video to
explain difficult or unfamiliar concepts,
including randomization, use of a placebo
(now referred to as the “comparison gel”),
and voluntary participation. To underscore
that participation in the trial is voluntary, the
video uses vignettes featuring a participant
from the Phase 2 study, as well as a volunteer
who enrolled and later chose to withdraw
from the trial. The video also depicts a pelvic
exam, a procedure that was unfamiliar to
most women in the trial communities.
Workshop participants noted that
because formative research often is conceptualized and perceived as primarily intended to
inform clinical trial processes, the data are
rarely analyzed, presented, or disseminated as
discrete research, and the richness of the
research design and findings can be lost.

Designing informed consent and other
processes for HIV prevention trials—such as
strategies for recruitment and retention of
participants, locating facilities, or developing
a community partnership—presents enormous challenges. The field is growing and
evolving rapidly, and many trials are being
planned in similar sites and communities.
Therefore, making the findings of formative
research more readily available across studies
could contribute significantly to improving
trial processes and to targeting and streamlining future formative research. For example,
when HPTN research staff learned from
Population Council staff about participants’
concerns regarding the pelvic exam, they
incorporated an illustration of a pelvic exam
into the HPTN consent materials. Workshop
participants strongly recommended that
researchers consider findings from formative
research as important in and of themselves,
and, whenever possible, allocate resources for
publishing, sharing, and disseminating formative research findings across trials.

Informed Consent Tools
As described above, all of the HIV prevention
trials represented at the workshop used a variety of additional educational tools and materials to enhance study volunteers’ understanding of trial concepts and procedures. Some of
the challenges and successes experienced in
developing and using these supplemental
materials are explored below.

Booklets
Illustrated booklets are used to provide information for many of the studies represented
at the workshop. Some were designed to provide general information about the research,
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whereas others are more comprehensive. For
example, the informed consent form for the
Carraguard Phase 3 microbicide trial provides basic required information (see box on
page 23: Carraguard Trial Outreach) according to regulatory guidelines, and the booklet
supplements the form, giving more details
and comprehensive information about previous testing of Carraguard and the placebo.
Workshop participants engaged in a lively
discussion about the usefulness of booklets
and how they could be, and actually are,
used. In response to a question about whether the women in the trials actually used the
booklets on their own, several study staff
members noted that participants in the trials
rarely seemed to refer to the booklet for information and preferred to have their questions
answered by a counselor. To underscore to
participants that the booklet contains answers
to many of their questions and can be used as
an ongoing reference, some trials ask counselors to refer to the information provided in
the booklet when responding to questions
during one-on-one or group sessions. Some
staff suggested that booklets help with
recruitment because women who are considering enrolling or who already are enrolled in
the trial show them to friends or relatives

who may be interested in participating.
During pretesting, potential participants
voiced specific opinions about the images,
color, and production quality of booklets.
Potential study volunteers felt that a wellprinted color booklet conveys a trial’s professionalism and its respect for participants.
Several experts at the workshop suggested
that using color can help participants understand and retain information because color
images look more lifelike than black-andwhite ones. Documenting the efficacy of
color in trial settings would be useful for providing evidence that more expensive production is cost-effective.
The booklet used in the HPTN 035
microbicide trial uses line drawings and a character, “Serena,” to explain many of the study’s
concepts and procedures. This multisite trial is
being conducted at eight sites in six countries,
and the materials, including the illustration of
Serena, were adapted to suit each setting (see
box on page 21). All HPTN trial materials
have undergone a two-stage pilot test, incorporating a number of revisions at both stages.
Serena was modified according to the results of
the pretests to elicit respect and confidence.
Although study staff intentionally designed
Serena to look familiar to the women being

Evolution of “Serena” for HPTN 035

In pretests, participants helped to develop Serena, used in the booklets for the trial. (Artwork by Denise Todloski)
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HPTN Booklets
United States

Health in Africa) trial of the latex diaphragm
to prevent HIV acquisition among women,
the HIV/HSV Partners in Prevention trial,
and the Carraguard Phase 3 microbicide trial.
All three are using video for its potential to
ensure consistency in how information is presented and to reduce the burden on staff by
providing essential basic information about
the trial. Video is also perceived as a more
engaging approach than print media, especially for people with low literacy. Staff in the
MIRA trial found that people at recruitment
sessions and participants tend to become
bored by written materials or by hearing staff
present trial information and indicated that a
video would help keep them interested. This
suggestion echoes participants’ recommendations from the Carraguard Phase 2 trial.
The Carraguard Phase 3 video uses vignettes to convey key aspects of the study that
participants in the Phase 2 trial found challenging: voluntary participation, communication
with a partner, the pelvic exam, and HIV test-

Information in booklets provided to participants
was adapted for each of the eight sites in six
countries.

recruited for the trial, pretesting indicated the
women’s strong preference for her to be a more
“aspirational” figure. Therefore, Serena was
redrawn to appear modern, attractive, and
affluent. One drawing in the booklet was
designed to make Serena appear reflective and
thoughtful as she considered whether to join
the study (see box on previous page). Instead,
potential participants thought the picture of
Serena with her forefinger on her lips made
her look worried, which could raise concern
among volunteers considering enrollment.
Similarly, participants in the Phase 2 Carraguard trial recommended that the illustrations
be more realistic than the cartoon style of the
Phase 2 booklet. The Carraguard Phase 3
booklet has a more professional look, with
more realistic illustrations, higher-quality
paper, and a glossier texture (see box below).

Carraguard Booklets
Phase 3
Phase 2

Video
Three trials represented at the meeting are
using videos to provide information for
recruitment and informed consent: the
MIRA (Methods for Improving Reproductive

Study participants in the Phase 2 Carraguard
trial recommended that illustrations for the
information booklet (left) be more realistic.
Changes were made to the Carraguard
Phase 3 booklet (right).
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ing. Other difficult concepts, including randomization and use of a placebo are explained
using animation. An educational consultant
worked with the trial team and the video production company to develop the script, and a
well-known and trusted actress is the on-camera
narrator in the video. Initial sections were pretested and adapted following focus-group discussions with community members and the community advisory groups at two of the trial sites.
Clinicians, community members, and the
research team were also involved in developing the video for the MIRA trial. The chair of
the ethics committee agreed to appear in the
video, helping to give a real face to the concept of the “ethical review.” Trial participants
respond positively to his presence in the
video, indicating that it conveys the study’s
professionalism and that their involvement
in the research is valued.
The efficacy of using video to improve
comprehension is still being evaluated. The
Population Council is conducting a formal
evaluation of the informed consent process in
the Carraguard Phase 3 trial, which will include an assessment of whether the video improves comprehension and has an impact on
individuals’ willingness to participate in the
trial. Anecdotal reports presented at the workshop suggested that study staff and trial participants find the video helpful, informative, and
interesting; women like seeing what they will
experience if they enroll in the trial and respond positively to the actress who narrates.
According to study staff, however, some women find the video boring or repetitive, and
some are frightened by the portrayal of the
pelvic exam and the HIV test. Despite the extensive work invested in developing
the Carraguard video and other supplemental
materials, a number of concepts seem to re-

main unclear to participants: why a placebo is
used and how the microbicide’s effectiveness
will be determined if participants use condoms.
Developing a video can be a complex
process, sometimes requiring a long lead time
before a study begins, which can make it difficult to accommodate protocol changes. Video
production can be especially complex in the
case of multisite trials that may use diverse
participants who speak different languages.
Even for sites only in South Africa, the Carraguard video had to be produced in four languages (Xhosa, Tswana, Zulu, and English) to
reflect the languages spoken at each site. Teams
for all three trials that use video (Carraguard,
MIRA, and Partners in Prevention) have also
encountered challenges in using the videos as
planned. Showing a video at all recruitment
venues may not be feasible; attracting the
attention of potential participants in busy clinic sites may be difficult; and bringing expensive projection equipment to the recruitment
sites can be cumbersome or even dangerous.
Video technology offers exciting possibilities for facilitating recruitment and informed
consent processes, particularly in large-scale
efficacy trials, and ongoing evaluation is needed to identify how video can best be used.
Such evaluations should consider not only
whether use of a video improves prospective
participants’ comprehension but also should
determine the extent to which video engages
their interest, standardizes provision of information, and reduces the burden on study staff.

ACASI
The BOTUSA Project PREP trial was the only
trial represented at the workshop that was planning to use audio computer-assisted self-instruction. As noted above, at the time of the workshop, the BOTUSA Project trial had not yet
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begun recruiting trial participants, so this system
had been pilot-tested but not yet implemented.
The ACASI method employs a touchscreen computer application session designed
to educate potential participants about the
study. Information is presented in film clips
with narrators talking through each screen.
Participants can select the language they prefer
to use from several choices. Some sections of
the instruction, such as basic trial information,
are required; others, such as information about
HIV transmission, are optional (HIV prevention information is pervasive in Botswana).
Participants can take as much time as they
need and have the option of exploring a number of issues in depth. A self-test is included at
the end of the session, and the results are
reviewed with a counselor to clarify any issues
that may be problematic, before signing the
informed consent form. As with video technology, ACASI should be evaluated for its effectiveness as an informed consent tool along multiple dimensions.

diverse supplemental materials is determining
what information should be presented to whom
at which point in the process, and using which
modes of communication. Workshop participants discussed these issues at length, and
although no consensus was reached, a number
of important points emerged. All trials conceptualized informed consent as a comprehensive
process that engages the broader community as
well as trial volunteers and participants. In
addition to informing participants about trial
procedures, risks, and benefits, it is crucial to be
transparent with the community and provide
information to reduce rumors, misunderstanding, and misinformation. As shown in the
example in the box below, trials employ different materials and strategies for conveying information to their various constituencies.
The MIRA trial emphasizes several key
messages in its community outreach: the purpose of the trial, the inclusion criteria, the need
for participants to be able and willing to give
their informed consent, and contact details.
Trial staff members feel that the most important
message to provide is the experimental nature of
the trial and that it is not known whether the
product works to prevent HIV transmission.
Additional details of the study are provided dur-

Providing Trial Information:
Audience and Tools
One of the complexities of implementing a
multistage informed consent process using

Carraguard trial outreach and informed consent tools
Tool

When used

Purpose

Flyers/posters

Before recruitment

To present basic study information to attract potential
participants

Video

Recruitment and/or
screening

To present key themes and difficult concepts
To standardize information presented

Booklet

Recruitment
Screening
Ongoing consent

To supplement the informed consent form
with details and illustrations

Informed consent form

Screening

To provide required information as simply as
possible (bullets; short sentences)

Gel instructions

Enrollment

To present details of gel insertion and applicator collection
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ing the screening and enrollment informed
consent processes. The Soweto community in
which one of the MIRA trial sites is located is
also the setting for dozens of other clinical trials. In this context, the MIRA trial has identified a critical need to inform the community
about the entire concept of informed consent
and has contracted with a local radio station to
present a monthly broadcast about research,
clinical trials, and informed consent.
All trials represented at the workshop
considered community outreach and informed
consent to be part of a holistic process of
partnership. Although developing general
guidelines concerning what information
should be provided to whom and at what
time may be possible, determining the levels
of information appropriate for various constituencies at different points in the process
may be feasible and appropriate only in the
context of specific trials and trial settings.
(See the section above on community
involvement and informed consent.)

the use of placebos and randomization. Although some trial participants can describe
and define placebos or randomization, few are
able to articulate why they are used in clinical
research. The uncertainty inherent in the scientific process can also be hard to convey, particularly in the context of clinical research
where there is likely some indication that a
product works but additional research—such
as the current trial—is needed for definitive
evidence. People’s tendency to associate the
medical establishment and scientific processes
with facts and certainty is amplified by their
urgent need for new products for the prevention and treatment of HIV/AIDS. Virtually
everyone at the workshop was concerned about
the issue of therapeutic misconception, especially against the backdrop of the acute need
for new HIV prevention technologies and the
implications for behavioral disinhibition.
During the third day of the workshop,
a subset of participants explored different
approaches to describing difficult concepts.
Workshop organizers had requested informed
consent and educational materials from a
number of trials that were represented at the
meeting and reviewed these informed consent
forms, study booklets, flip charts, fact sheets,
pamphlets, and videos prior to the workshop.
This review, although not comprehensive,
provides some concrete examples of conceptual approaches to presenting and describing
the complex information and concepts
associated with an HIV prevention trial
(Bracken 2005).*
Some of the key points are highlighted
below:

Explaining Difficult Concepts
The workshop participants engaged in a lively
brainstorming, discussion, and debate about
which clinical trial concepts are the most challenging to convey. Of the wide range of topics
mentioned, several were common to many trials and settings. For example, the broad notion
of research and experimental scientific work
was hard to grasp and unclear to many potential trial participants, and most study teams
struggled with ways of describing and depicting the scientific process. Many people have
difficulty understanding the concepts behind

* These examples are being used in different trials and were developed based on different degrees of formative
research and pilot testing. How effective they are at conveying information clearly to trial volunteers and participants is not known in every case, so these should not be considered at this time as “best practice.”
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• Most of the materials reviewed include
both text and visual images (drawings,
pictures, and/or diagrams) to convey or
reinforce particular concepts. The style
of the printed materials varies; some
materials use multiple colors for images
and fonts, and others use color selectively to emphasize key terms or points.
Interestingly, many materials developed
for different trials and settings use red to
highlight important concepts or words,
although it is not clear whether the use
of red in this way carries the intended
meaning in all contexts.

ipants, is conveyed through a range of
images: test tubes and microscopes; a
magnifying glass; clinic interiors; and
doctors and scientists in white lab coats.
Some workshop participants were skeptical about whether such images are meaningful to trial volunteers who have little
or no experience or associations with
items like microscopes. Researchers conducting the Carraguard Phase 3 trial
noted that one of the IRBs had required
them to include a “scientist in a white
coat” at the end of the video to reinforce
the experimental nature of the product
and to itemize the risks and benefits of
the trial for research participants.

• Most materials begin with a “problem
statement,” or broader rationale for
undertaking the research and developing new approaches or products for HIV
prevention. Most start with a description
of HIV/AIDS, followed by a discussion
of current methods to prevent transmission of the virus, including information
about safer sex practices. Several of the
materials highlight the limitations of
current prevention strategies (for example, that the use of condoms is controlled by men) and acknowledge that
consistent use of current approaches is
not feasible for many people. Some of
the materials also include other relevant
public health messages.

• Randomization is explained by using
images associated with chance, such as
rolling dice or a lotto machine; a computer is depicted to underscore that no person decides whether a trial participant will
Randomization

• Some materials include a description of
scientific processes, and emphasize the
multiple stages of research conducted to
determine product safety and efficacy.
They describe where the current trial fits
into this overall process.

Images of objects associated with the idea of
chance—rolling dice—were used to explain that
participants are selected randomly for a study’s
intervention and control groups. Top illustration
from the Carraguard Phase 3 trial; bottom from
the BOTUSA PREP trial.

• The concept of research, which may be
unfamiliar to many potential trial partic-
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be in the intervention or control group.
However, workshop participants acknowledged that finding a consistent way of
illustrating this concept for studies with
sites in multiple countries can be difficult.

as a barrier,” or “protects us from getting
sick by enabling our immune system to
recognize and destroy the organism that
causes disease.”
• Most of the materials used either explicit
or suggestive images for sensitive issues.
For example, some materials used drawings of shoes or a pile of clothes to suggest sex, whereas others depicted a nude
man and woman lying together (see box
below). Some participants expressed concern that using explicit materials that
may be taken home or seen by other
people may stigmatize the study or the
participants. One study team chose to
include the illustration of a pelvic exam
only on printed materials used at the
clinic site but not in materials that participants took home.

• In describing a placebo, the descriptions
in the materials emphasize that the study
product and the placebo are identical
Placebo

Drawings in the Carraguard Phase 3 video
were used to emphasize that the product and
the placebo look the same and are used in the
same way but that the placebo is inactive.

• One particularly complex issue to convey
is that of serodiscordance, a critical and
potentially highly charged dimension of
the Partners in Prevention HSV/HIV

except that the placebo is “inactive,” or
“doesn’t have [name of active ingredient] in
it,” or that “one contains [the active ingredient] and one does not.” One trial refers
to the placebo throughout as the “comparison gel.” Other suggested approaches
to explaining the use of a placebo include
using images of vitamin-enriched juice or
milk, costume jewelry, or imitation products such as CokeTM and Diet CokeTM.
Specific analogies must be drawn from
and tested in each setting to ensure that
the example is clear and relevant.

Sexual Activity

• Different trials describe the study drug’s
or product’s posited mechanism of
action with varying degrees of complexity by saying that it: “blocks HIV,” “acts

Depending on the study site, the materials
in various Carraguard trials used explicit
images (top-South Africa) or suggestive
ones (bottom-Thailand) to suggest sex.
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Pelvic Exam

without testing. This image is used in
print materials and also in animation in
the study video.
• The critical issue of partial effectiveness
was not addressed directly in any of the
materials. Meeting participants tended to
agree that when a trial product’s efficacy is
unknown, introducing the concept of
partial effectiveness can be too confusing.
The examples above demonstrate the creativity and care that researchers are applying
in an effort to explain these complex concepts. They also underscore the difficulty of
knowing what images to use, what they convey, and whether they serve to make the concepts clear. Pretesting the images and text to
be used in materials for clinical trials and
adapting them as the setting demands are
critical for ensuring that they convey the
right messages and facilitate rather than compromise peoples’ understanding. Many of the
approaches, such as the use of the baobab

Some participants expressed concern that
being too explicit in materials that may be
taken home or seen by other people may
stigmatize the study or the participants. One
study included illustrations of the pelvic exam
on print materials used only at the clinic site.
Top picture from BOTUSA Project PREP trial;
bottom from HTPN.

Serodiscordance

trial. To help convey the notion of serodiscordance and encourage couples to be
tested for HIV infection, the researchers
use an analogy of baobab trees infected
with termites. Using pictures and text (see
box on right), they show drawings of two
baobab trees side by side. The drawings
indicate that termites can attack and
slowly destroy one or both of the trees in
the same way that HIV can infect one or
both partners and slowly kill. You cannot
tell from afar which tree has termites, nor
can you tell which partner may have HIV

To convey the notion of serodiscordance, two
baobab trees are depicted. Although the trees
look similar, one is infected with termites that
can destroy one or both of the trees. The
illustration is used as an analogy for HIV, which
can infect one or both partners but cannot be
diagnosed without testing. Illustration from
Partners in Prevention HIV/HSV study.
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tree analogy, may be effective in some settings
but would not be relevant in others. Workshop
participants agreed that it is important to
continue to experiment with different approaches and images for conveying complex
concepts, to evaluate them rigorously, and to
exchange information about what works.

monitoring the informed consent process.
Staff undergo a two-day training on informed
consent, starting with a general review of
informed consent requirements and the specific approach adopted for the trial. Staff then
review the supportive materials, including a
page-by-page review of the booklet. They
engage in brainstorming and role-playing
using visual aids, administering the comprehension assessment, and reviewing the consent forms. Based on results of monitoring,
additional “booster” training may be added as
a refresher or to emphasize particular elements of the informed consent process. As
with all other elements of good clinical practice for trials, sufficient resources must be
allocated in the trial budget for ongoing
training.
HIV prevention trials are experimenting
with a wide range of tools and approaches for
conveying complex issues. Developing, producing and employing these tools can be
costly. Evaluating the efficacy of different
tools is important and requires the resources
and the commitment of the broader trial staff
and infrastructure. Not all of the current trial
sponsors or trial staff have been willing to
commit resources and staff time to such formal evaluation.

Training
Ensuring that trial staff can and do use the
materials developed for the informed consent
process is essential for integrating them effectively into the trial. Even the best materials are
of limited use if study staff do not use them
appropriately and consistently. For example,
the BOTUSA Project has developed a number
of strategies to ensure the effective implementation of the informed consent process in the
research clinic. These include training in good
clinical practice, translation and back-translation of all materials, staff training in informed
consent procedures, practice drills with observation, and quality-assurance observations during the study.
Implementing HPTN’s comprehensive
approach has also required training to familiarize staff with using various tools and
approaches and additional work to develop
standard operating procedures and ways of
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Assessing Comprehension
Many HIV prevention
trials are currently grappling with how best to measure potential participants’
understanding of trial issues.

ed in developed countries, the relevance of
these theories and approaches may vary
depending on the respondent’s culture, age,
level of formal education, and gender. Even
so, the field of adult learning offers a number
of perspectives and insights useful to assessing
informed consent.
Adult learning theory suggests that individuals understand and retain information
differently depending on how it is presented.
In general, people are apt to forget information they hear; they are more likely to remember information they see; and they are most
likely to understand and remember information they use (see box below: Communication
Approaches). Comprehension and recall are
also strongly influenced by the level of abstraction of the information presented.
According to Bloom’s commonly used taxonomy (Bloom 1956), three levels of learning are
particularly relevant to the informed consent
process: knowledge of factual information;
comprehension (interpretation of information
in the respondent’s own words); and application of knowledge or generalization of knowledge to other situations (Moser 2005).
In developing an assessment approach, it
is critical to consider carefully the types of
questions that will elicit the relevant information and thought processes. Will a question
measure the short-term recall of facts or the
more sophisticated and nuanced concept of
“understanding”? Knowledge questions elicit
factual answers and test recall or the ability to
recognize critical information. Comprehension questions require the potential participant to identify information about content
and to translate that information into anoth-

How do adults learn? How should information about a trial be presented to ensure that
a volunteer’s consent is truly informed?
Should comprehension of particular concepts
and study procedures be considered essential
where volunteers must demonstrate their
understanding or they will not be allowed to
enroll in the trial? How should those issues
be determined? What methods should be
used to assess comprehension and what are
the advantages and disadvantages of each?
How can information gleaned from such a
process best be used for adapting and
improving the informed consent process and
materials? Workshop participants considered
theory and practice in debating these issues.

Adult Learning
The field of adult learning posits a number of
theories and approaches to understanding
how adults learn. Based on research conduct-

Communication Approaches
Most effective

Least effective

Teaching others
Immediate application
in real situation
Practice through doing
Discussion
Demonstration
Audiovisual
Reading
Lecture
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However, for assessing comprehension of
complex issues, such an approach can be limited. Closed-ended questions can create the
illusion that the trial volunteer has understood information when all that is really
being measured is his or her short-term ability to repeat what he or she has been told.
Developing the questions and the overall
instrument can present difficulties. Choosing
the precise wording and terms to use is especially complicated for trials conducted at
multiple sites and in more than one language.
By their nature, true/false questions include
incorrect statements that can confuse volunteers. Study staff have often expressed concern about voicing and repeating information
that is not correct. As a result, true/false
assessments tend to be skewed to “true” statements. Finally, the true/false approach is not
familiar in many settings; it may confuse trial
volunteers, and they may consider it impolite
or inappropriate to tell the counselor or
provider that a statement she or he has made
is “wrong.” Quantitative measures, while
most objective, are minimally effective when
used alone to elicit information about understanding of complex and varied issues.
In contrast, qualitative assessments that
use open-ended questions generally encourage
people to say more and reveal more clearly
whether information has been understood.
Qualitative assessments are better for helping
to initiate meaningful discussion through
which a volunteer’s questions can be
answered. Staff can also get a sense of
whether a participant can apply information
to deciding whether to participate in a clinical trial and to following the protocol. The
open-ended approach allows the participant
to respond in his or her own words in a dialogue consistent with the spirit of informed

Sample Assessment Questions
Knowledge: From the list, choose the correct number of times you need to visit the
clinic during the study.
Comprehension: Why are we testing this
product? To see if it prevents HIV/AIDS
or cures it? Explain the difference between
“prevent” and “cure.”
Application: Tell me what will happen
before you have sex. Where will you keep
the product? How will you use it? When
will you apply it?

er form to display understanding of that information. Application questions can be used
to explore the participant’s ability to apply
knowledge to solve problems. All three
approaches can be useful for assessing
informed consent. When feasible, combining
methods and techniques may be the most
comprehensive and productive approach.

Quantitative or Qualitative Approaches
Researchers designing informed consent assessments confront a choice about whether to
employ primarily quantitative approaches,
which use closed-ended questions (for example,
true/false or multiple choice) or qualitative
approaches, which feature open-ended questions. Closed-ended questions are generally better for eliciting specific information, one-word
answers, or for checking facts. This approach
has a number of advantages: it is relatively simple to administer, the evaluation is relatively
objective, and less staff training is required. A
quantitative approach has been used in HIV
vaccine trials, including the AIDSVax trial,
in which volunteers were administered a true/
false test on a number of key issues prior to
signing the informed consent form.
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consent. However, such an approach is subjective in that it requires the staff to make judgments about a volunteer’s level of understanding and eligibility to enroll in the trial, based
on varied responses. Qualitative assessments
require more extensive staff training and
greater amounts of staff time and skill than
the quantitative approach.

Issues that participants must comprehend
may vary according to the specific product
being tested. For example, in CONRAD’s
Phase 3 trial of the candidate microbicide cellulose sulfate, in which only women are
enrolled, the comprehension assessment
emphasizes the need to practice contraception. In a Phase 3 efficacy trial of the candidate HIV vaccine AIDSVax, in which male
injecting drug users were enrolled, the comprehension assessment emphasized safe injection practices and included awareness of vaccine-induced seropositivity.

What Do Participants Need to Know?
Although a volunteer’s full comprehension of
all elements of a trial is the aim of informed
consent efforts, achieving this level of understanding may not always be possible. As one
speaker pointed out, a discussion paper from
the Nuffield Council on Bioethics notes that
“fully informed consent is unattainable”
(NCB 2002). Workshop participants discussed and debated what level of understanding volunteers should be required to have in
order to participate in a trial. How much
information is enough for making an
informed decision to enroll in and continue
to participate in a trial? Are there particular
issues that all volunteers must clearly comprehend in order to enroll? What are they and
how should they be determined?
Although no clear consensus was reached
at the workshop, participants considered a
number of issues to be critical for trial volunteers to understand: the purpose of the research; the experimental nature of the trial;
the uncertainty about the trial products’ efficacy in preventing HIV infection; and the
need to continue other risk-reduction practices during the course of the trial. Participants in all trials also were required to have
some knowledge about the concepts of randomization, placebo, and blinding, as well as
of key issues related to study procedures, risks,
benefits, voluntarism, and confidentiality.

Implementing Comprehension Assessments: Experiences from the Field
Ongoing HIV prevention trials are using a
number of approaches to assess comprehension as part of the informed consent process.
These assessments generally are being conducted in an instrumental fashion for the
purposes of the particular trial and its implementation, rather than as a way to contribute
to a broader empirical understanding of the
informed consent process.
The HPTN 035 trial is currently using
an open-ended assessment consisting of eight
items (see box on page 32: HPTN 035
Enrollment Informed Consent Comprehension Checklist) that reflect the required elements of informed consent according to the
US Code of Federal Regulations (see box on
page 6: Basic Elements of Informed Consent). Within each of these items are more
specific elements, “must knows” that volunteers are required to answer correctly in order
to be enrolled. The assessment is conducted
in a conversational style. If, in the course of
answering a particular question, a volunteer
also answers another question, she is given
credit for both responses. Interestingly, the
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HPTN 035 Enrollment Informed Consent Comprehension Checklist, Version 1.0


Open-Ended Question/Statement

Required Points of Comprehension

1. Please describe your understanding
of the purpose of the study.

Study is testing two experimental gels
Testing to learn if gels are safe
Testing to learn if gels may prevent HIV
Study may not prove gels work
Asked to use condoms and perhaps gel
with each act of vaginal sex
Have pelvic exams and HIV tests
Come for monthly visits for up to 30 months
Hot get pregnant in next 30 months
Gel may irritate skin inside or outside vagina
Gel may have other side effects
Possibility of social harms
Free to make her own decision about joining
No effect on access to care when decide
to join or not
There are different gels
Not everyone receives a gel
No one knows who receives which gel
Participant information is kept under
lock and key
Only people working on the study have access
Reimbursement, clinical care, benefit to
community (must mention at least one)
Must articulate how to contact study staff

2. What do you understand that you
are being asked to do in this study?

3. What do you understand about
possible risks that might happen
as a result of being in the study?
4. What will happen to you if you
decide not to join the study?
5. Please tell me about the different
groups of women in the study.
6.How will the information about
you be protected?
7. What are the benefits to you of
participating in this study?
8. What should you do if you have
any questions about what is
happening in the study?

Comments

Outcome:

Optional comment categories:

 Demonstrated comprehension of all required points, decided to enroll

a. Answered correctly on first try.







in study.
Demonstrated comprehension of all required points, decided NOT to
enroll in study.
Demonstrated comprehension of all required points, deferred enrollment
decision to another visit.
Did not demonstrate comprehension of all required points (yet), needs
more time/discussion, rescheduled for another visit.
Unable to demonstrate comprehension of all required points, consent
process discontinued.
Other (specify): _________________________________________

b. Could not answer at first, but answered
correctly after some probing/discussion.
c. Answered incorrectly at first, but
answered correctly after discussion.
d. Not able to answer correctly at this
time.
e. Other (describe)

Staff signature:

HPTN working group initially chose a closedended approach for its relative ease and consistency, but after considering its limitations, the
group switched to an open-ended strategy. The
assessment tool benefited from continuous in-

put from the community and from pilot testing and adaptation at all of the trial sites. It is
being used successfully at all of the sites to assess
comprehension before women can enroll in the
trial, and the team plans to use the same instru-
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ments for assessment among a random sample
of trial participants throughout the trial.
CONRAD’s Phase 3 cellulose sulfate trial
also involves a conversational approach to the
assessment of comprehension, using questions
framed as “correct” and “incorrect.” Staff in
this trial assess comprehension at the enrollment informed consent session during which
volunteers must answer five main questions
correctly before signing the informed consent
form. Volunteers do not need to answer in
specific terms; the counselor makes a judgment about whether the woman demonstrates
comprehension. If she does not answer a
question accurately, staff will discuss and
explain it further. If concerns remain about
her comprehension of key issues, staff will
schedule another appointment for further discussion if the volunteer wishes. The same tool
will be used with trial participants every three
months to check participants’ understanding.
Information will be repeated and reinforced
during these sessions if necessary, but women
will not be asked to leave the trial if they cannot answer correctly.
In the BOTUSA Project’s tenofovir
PREP trial, volunteers who wish to enroll in
the study are required to take a comprehension test consisting of 20 true/false questions.
Participants must answer 80 percent of the
questions correctly, including two questions
that relate to the unknown efficacy of the test
product and the risk of HIV infection. If necessary or desired, this test can be taken again
once. Informed consent is then administered
orally, and a copy of the informed consent
form is given to the participant. The test will
be readministered every six months during the
trial, and concepts that are not well understood will be reinforced at that time.

Meeting participants had varying views
about how much information, support, and
retesting should be available before a potential participant is deemed ineligible to enroll.
In the HPTN 035 trial, a volunteer can
return over the course of several days to continue the informed consent process. Other
trials allow a volunteer to ask questions in
order to clarify information and to be reevaluated a limited number of times before being
judged ineligible for enrollment. For participants already enrolled, these assessment tools
are not used to withdraw volunteers; rather
they are used for evaluation, monitoring, and
quality improvement.
Because such assessments can be interpreted as tests and can be intimidating to
trial volunteers, several researchers suggested
that trial staff present the assessment as a
check to determine if the staff has done a
good job of explaining the study rather than
as a test for the participant. One researcher
noted that participants are told, “We are not
evaluating you; we are evaluating us.”

Staffing and Training
A key component of informed consent implementation and assessment is staffing and staff
training. As one speaker noted, the best informed consent tool, assessment, or process is
only as good as the person or people charged
with implementing it. As described above,
open-ended approaches generally require more
sophisticated and nuanced judgment on the
part of staff and, therefore, necessitate considerable initial training as well as ongoing monitoring and support. Enrollment targets may
create a disincentive for staff to determine
that a trial volunteer does not understand the
information well enough to enroll. One inves-
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tigator noted that this tension is acknowledged openly and that staff are advised that
volunteers who have difficulty demonstrating
their understanding for informed consent purposes are less likely to remain in the trial and,
therefore, may not be suitable participants.

The open-ended approach, with its conversational mode that allows for discussion of
questions and issues in respondents’ own
words, seems to be the best strategy for assessing the complex array of recall, comprehension, and application required for ensuring
genuinely informed consent. Depending on
the protocol, the individual, and the cultural
setting, people may respond very differently to
open-ended questions. Therefore, pretesting
and adaptation of instruments are essential for
producing suitable assessment tools for each
trial setting. Identifying a set of “deal-breaker”
topics that participants must clearly comprehend is critical. Assessments can be used to
identify common problem areas to be addressed
by modifying processes or developing supplemental materials. Although assessments that
elicit more information and discussion are
generally most useful for determining prospective participants’ understanding, the constraints
of time, availability of skilled staff, and other
resources may restrict their use in practice.

Feedback and Adaptation
Assessments of volunteers’ understanding can
provide important information for supplementing or adapting informed consent materials or approaches. In addition to determining an individual volunteer’s eligibility, assessments can highlight areas that may need to be
revised or adapted if volunteers consistently
have difficulty understanding them. Supplemental materials, such as frequently asked
questions, can be used to respond to new
issues that emerge. It is important for trials to
build in a process that allows for feedback and
course correction using results of informed
consent assessments, staff feedback, and contextual changes.
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Monitoring and Evaluation of the
Informed Consent Process
Formal evaluations of informed
consent processes are necessary
for determining whether the
resources invested in materials,
training, and implementation
actually result in improvements
of the informed consent process.

ing video; shorter, more readable forms;
increased discussion time; and short quizzes
used to confirm understanding and provide
feedback on test results.
This review suggested that extended discussion with a counselor or nurse has the
greatest effect on improving potential participants’ understanding. Evidence for the efficacy of other interventions was mixed.
Although these findings are instructive, the
degree to which they can be generalized to
other settings, populations, and trials is
uncertain. As described during the workshop,
researchers conducting clinical trials continue
to develop and incorporate a range of approaches into their informed consent processes. It is, therefore, important to evaluate rigorously the efficacy of these expanded informed consent processes in a range of trial
types, populations, and contexts. Research
designed to distinguish between participants’
memorization of facts and their comprehension of the information provided is especially
valuable. Such research is particularly important for the conduct of studies in developing
countries in light of the paucity of information available about such interventions and
the growing attention to study processes and
research ethics—including informed consent.
One speaker noted that any such evaluation depends on gathering high-quality data,
and he enumerated several key elements for
doing so (Sugarman 2005). Most important,
the evaluation should be independent and the
results kept confidential. The process should
not interfere with the clinical research process,

As previously noted, few such evaluations
have been undertaken in clinical research
conducted in developing countries, particularly in prevention trials that enroll healthy
people. Among the trials represented at the
workshop, only the Population Council’s
Carraguard Phase 3 trial will include a formal
evaluation of the informed consent process.
The workshop included a presentation of
a recent review of research on improving
informed consent (Flory and Emanuel 2004).
The review was based on a broad search of
Medline and other sources; it included 42
controlled trials of interventions that compared a “standard” consent process to an
“enhanced” consent process and that measured understanding quantitatively. Of these
studies, 30 were published in the formal literature and five were related to HIV/AIDS,
although only one was conducted in a developing country. The clinical trials in which the
informed consent evaluations were embedded
included randomized controlled trials, longitudinal trials, and trials with nonrandom
allocation for a range of diseases and interventions. Interventions to improve understanding included four main approaches that
mirror those being used in some HIV prevention trials: multimedia presentations, includ-
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should pose minimal burden for staff, and
should be practical and simple (Lavori et al.
1999; Sugarman et al. 2005). The research
team and sponsor must support the evaluation. A sound study design is essential, and
teasing out the complexities of participants’
recall, comprehension, decisionmaking, and
potentially varied sources of information and
experience can be challenging (Sachs et al.
2003). Finally, staff must be trained in implementing the informed consent study and in
interpreting and applying the results.

tiveness and covering the costs of informed
consent. Defining “costs” will likely vary
across different actors—the participants, the
researchers, the community, and the research
institution. The standard for effectiveness
may vary according to a number of factors.
For example, the understanding of participants in experimental research should be
higher than that of those receiving treatment:
the higher the potential risk, the more rigorous the measure of comprehension; and the
more vulnerable the participant, the greater
the concern about protections afforded by
informed consent. In considering cost, it is
important to acknowledge that current
research is taking place in a historical context
of poorly conducted trials that created a legacy of exploitation and suspicion.
Evaluating informed consent processes
is important, but it is also challenging and
potentially controversial. Virtually all trials fall
short of “perfect” informed consent. As evidence presented at the workshop indicates,
certain issues remain difficult for people to
understand despite concerted and creative
efforts to explain them. Therefore, evaluating
informed consent processes—and disseminating the results—can be risky for trial sponsors. Given that perfection is unlikely to be
achieved, when is the investment in informed
consent sufficient? How willing will sponsors
be to disclose the less-than-perfect results of
such an evaluation? How can findings about
best practices in informed consent be shared?
Navigating these questions may present challenges as great as those of conducting and
evaluating informed consent itself.

Cost and Cost-effectiveness
Costs associated with an informed consent
process are just one dimension of a broader
ethical debate on justice surrounding the conduct of research in resource-poor settings that
also includes discussions of standard of care
and access to the product being tested.
Although costs of even an enhanced informed
consent process are likely to be only a small
part of the budget of a clinical trial, they may
be significant and must be weighted against
other investments and considerations in managing the research process, protecting the welfare of participants, and communicating the
results to key stakeholders. Evidence of costeffectiveness is an important factor in convincing sponsors to continue to support
investment in informed consent materials and
processes (Townsend and RamaRao 2005).
Evaluating cost-effectiveness requires
determining a standard for effectiveness that
factors in both financial and nonfinancial
costs. Assessment processes must clarify the
roles of various stakeholders in defining effec-
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Conclusion and Recommendations
Several primary themes
emerged from the presentations and wide-ranging
discussion at the workshop.

researchers in other fields to adopt such an
approach but also can provide oversight bodies like ethics committees with better standards for judging the adequacy of informed
consent processes.
A range of potential benefits of an expanded approach has been posited. Participants’ improved initial comprehension of the
study requirements may lead to efficiencies
by improving ratios for screening/eligibility
and eligibility/enrollment. Greater initial
comprehension, reinforced throughout the
trial, may also result in improved continued
comprehension of and adherence to study
requirements during the trial and reduced
therapeutic misconceptions or behavioral
disinhibition. As noted above, gathering
empirical evidence to demonstrate the value
of such an approach is important and can be
achieved by ongoing testing of participants’
comprehension, by monitoring community
responses to the study, and by documenting
participants’ adherence to the study protocol.
Such evidence can inform adaptation and
improvements of the informed consent
process; it can be used to justify to investigators, communities, trial participants, and
sponsors the effort, time, and cost associated
with developing and implementing a comprehensive approach. Several workshop participants noted the importance of justifying continued investment and experimentation in
informed consent among trial sponsors and
within large international organizations that
sponsor research. Rigorous evaluation of
informed consent processes can provide evidence to show whether they improve the

First, HIV prevention trials are incorporating
expanded informed consent processes that
employ innovative materials and approaches.
This commitment reflects researchers’ recognition of the complexity of ensuring
informed consent and of their ethical responsibility to do so. Second, the role of community is widely recognized as integral to
research and specifically to informed consent.
The degree to which these trials include community members and leaders in the informed
consent process is striking. The community is
provided with information about the trial,
and community input is solicited about
informed consent approaches and in the
review of materials and strategies. Finally,
workshop participants agreed that it is critical
to demonstrate through empirical evidence
that expanded informed consent processes
such as those presented enhance the conduct
of a clinical trial as well the informed consent
of trial participants.
Although many of the trials represented
at the workshop are investing considerable
time and effort to improve the informed consent process, this practice is not the norm in
clinical research. For many investigators, staff,
and trial participants, informed consent
remains a formality reduced to a form and a
signature. Empirical evidence demonstrating
how to improve informed consent and the
benefits of a comprehensive informed consent
program may not only help to convince
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expressed interest in continuing to share
information and develop strategies for evaluating specific informed consent tools and
overall processes, possibly through an ongoing working group. A number of participants
were particularly keen to look at the comprehension assessments in greater depth to share
strategies and ideas.
Specific recommendations for follow-up
actions that emerged from the meeting include:

overall conduct of the trial as well as its ethical dimensions.
Staff and researchers should continue to
share information across studies regarding specific strategies for presenting information and
for maximizing and assessing participants’ comprehension. In addition to building evidence
for continued investment, as described above,
such exchange also can contribute to resolving
common challenges, from decisions about
what media and strategies to use to developing
staff-training curricula to selecting specific
approaches for conveying complex concepts
such as randomization and use of placebos.
Several workshop participants thought that
determining which tools and approaches work
and have the greatest impact would be useful
so that researchers can focus on those. Others
cautioned that it is unlikely that there is one
answer to this question and that research will
likely point to a range of valuable approaches
that can be deployed according to the setting,
the trial, and the population.
Several participants suggested that the
design and results of formative research
should be treated as discrete and important
research findings rather than simply as an
instrumental way to inform trial design. This
approach would contribute to these findings
being shared and used across trials and
increase overall knowledge essential to the
conduct of HIV prevention research. It could
also help elevate the role that such formative
research plays within trials in developing
informed consent and other trial processes.
Participants attending the workshop were
struck by the opportunities presented by the
“natural experiment” now underway as many
HIV prevention trials experiment with innovative approaches to informed consent. Many

• forming a working group among staff and
researchers involved in informed consent
in HIV prevention trials to identify specific research priorities and strategies; to
exchange information and ideas; to look
closely at comprehension assessments; and
to continue to develop research design
and advocacy strategies for conducting
overall evaluations of informed consent
processes in ongoing trials;
• convening a follow-up workshop for
study staff and researchers in order to
address informed consent with activists
and community members;
• advocating for formative research to be
analyzed and disseminated more widely;
and
• continuing to capitalize on the energy,
creativity, and commitment being
brought to this field.
Finally, although participants acknowledged that some aspects of informed consent
remain very difficult, one suggested that
informed consent be seen as a kind of “standard of care.” The community has a responsibility to continue to evolve and improve
approaches and standards for informed consent, even if they may never be perfect.
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the Population Council/Family Health
International Workshop on Informed Consent
in HIV Prevention Trials, New York, 16–18
May.
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Glossary
ACASI
Audio computer-assisted self-interviewing, a datacollection technique in which the respondent uses
headphones connected to a laptop computer to
listen to questions that have been digitally recorded and keys his or her responses directly into the
computer. Because of the privacy that it provides,
this methodology, developed at Research Triangle
Institute, has proved to be a successful means of
gathering sensitive or personal information.

Behavioral disinhibition
Risk-taking behavior; for example, an increase
in high-risk sexual behavior that is based on
perceived safety or protection due to use of
condoms. In a clinical trial, a participant might
feel protected by the test product and engage in
risky behavior.
BOTUSA Project
A collaboration between the Botswana Ministry
of Health and the Global AIDS Program
(GAP) of the United States Centers for Disease
Control and Prevention (CDC). The BOTUSA
Project provides technical assistance, consultation, and funding; implements programs; and
conducts research with the Botswana government and other local and international partners
for prevention, care and support, and surveillance of HIV/AIDS, tuberculosis, and sexually
transmitted diseases.

Acyclovir
An antiviral agent used orally or topically to treat
herpes infections of the skin, lip, and genitals;
herpes zoster (shingles); and chickenpox. Used in
treatment of herpes simplex virus type 2 (HSV2), acyclovir decreases the intensity and duration
of outbreaks but does not eradicate the infection.
AIDSVax®
An experimental vaccine developed by the
biotechnology company VaxGen for the potential prevention of transmission of HIV infection. Made with genetically engineered proteins
similar to a protein on the outer coat of the
virus, the vaccine was intended to stimulate the
immune system to generate antibodies to the
gp120 portion of the virus. In the first largescale human trials of a vaccine designed to prevent transmission of HIV infection, the vaccine
did not prevent transmission in study populations in North America and Europe (results
released in February 2003) and Thailand
(results released in November 2003).

BufferGelTM
A candidate vaginal microbicide developed by
ReProtect; an acid buffer that keeps the vagina
acidic even in the presence of semen and creates
a physical barrier that stops or slows down the
passage of pathogens into the vaginal and cervical walls. BufferGel is currently undergoing
acceptability, safety, and effectiveness trials; it is
expected to work as a contraceptive and may
protect against HIV, HPV, HSV, chlamydia,
and gonorrhea.
Carraguard®
A candidate microbicide gel, developed by the
Population Council, made from carrageenan (a
substance derived from seaweed); an attachment
inhibitor that provides a physical barrier
between pathogens and vulnerable cells in the
cell wall (epithelium) of the vagina. Laboratory
tests have shown that Carraguard (formerly
known as PC-515) blocks infection by HIV,

Antiretrovirals
Chemical agents that are destructive to retroviruses either by disabling them or by preventing
them from multiplying. Antiretrovirals are used
to treat HIV/AIDS; different classes of antiretroviral drugs act at different stages of the HIV life
cycle and are often used in combination.
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HSV-2, HPV, and gonorrhea both in vitro and
in vivo and does not have contraceptive properties. The Population Council is currently conducting a large-scale Phase 3 efficacy and safety
trial of Carraguard in South Africa to learn if it
prevents sexual transmission of HIV.

Diaphragm
A contraceptive device; a dome-shaped cup
made of thin, flexible rubber that fits over the
cervix and acts as a barrier to prevent sperm
from entering the uterus by blocking the cervix.
To increase protection, a spermicide is put into
the diaphragm and along its edges before insertion. Currently, a trial is underway in South
Africa and Zimbabwe to test the effectiveness of
the latex diaphragm used with a lubricant for
preventing heterosexual transmission of STIs,
including HIV, among women (see MIRA).

Cellulose sulfate (CS)
A candidate vaginal microbicide developed by
CONRAD; cellulose sulfate (CS) is an attachment inhibitor that provides a physical barrier
between pathogens and vulnerable cells.
Preclinical trials showed the potential of CS to
act as an effective guard against both unwanted
pregnancy and STIs, including HIV. Currently,
two safety and efficacy trials of CS are being
conducted by Family Health International
(FHI) and CONRAD.

Effectiveness
The extent to which an intervention or substance produces a desired effect under field-use
conditions or conditions approximating field
use; the ability to produce a specific result or to
exert a specific measurable influence. (See also
Efficacy.)

CAB/CAG
Community advisory board or group, a group
composed of diverse volunteers from a community—including activists and advocates, local
professionals, and/or study participants—to
provide input into clinical trials taking place in
the community. The primary role of a
CAB/CAG is to ensure sensitivity to local context and inclusion of community input into the
research process. CABs/CAGs provide an
explicit opportunity for those affected by
research to contribute to its development,
implementation, and evaluation.

Efficacy
The ability of an intervention or substance to
produce the desired beneficial effect in expert
hands and under ideal circumstances; in pharmacology, the ability of a drug to produce the
desired therapeutic effect. (See also Effectiveness.)
Ethics committee
Often called an institutional review board
(IRB), a committee or other group formally
designated by an institution to review, to
approve the initiation of, and to conduct periodic review and oversight of research involving
human participants. (See also IRB.)

CONRAD
A research organization dedicated to improving reproductive health, particularly in developing countries where the need is greatest,
by supporting the development of better, safer,
and more acceptable methods for preventing
pregnancy and the spread of sexually transmitted infections, including HIV/AIDS. CONRAD is currently conducting Phase 3 clinical
trials of cellulose sulfate as a vaginal
microbicide.

Formative research
Research that is conducted in a community
before a trial, project, or intervention is designed
and implemented in order to help researchers to
identify and understand the interests, characteristics, behaviors, attitudes, and needs of the tar43
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get population(s); to design research, programs,
services, or products that are responsive to the
needs of the target population(s); to identify
barriers; to tailor messages; and to ensure that
programs are feasible and acceptable to the
study community. Methodologies can include
surveys, focus-group discussions, in-depth interviews, use of key informants, participant observation, or other community assessments.
Participation of stakeholders in formative
research contributes to producing a higherquality research project by maintaining focus
on issues important to the community.

HIV seroconcordance
A situation in which both partners in a couple
are of the same HIV serostatus—either both are
HIV-positive (infected with HIV) or both are
HIV-negative (not infected with HIV).
HPTN
HIV Prevention Trials Network, a worldwide
collaborative clinical trials network that develops
and tests the safety and efficacy of nonvaccine
interventions designed to prevent the transmission of HIV. Building on experience gained and
relationships established as part of HIVNET
(see above) and established in 1999 by the
Division of AIDS (DAIDS) of the National
Institute of Allergy and Infectious Diseases
(NIAID), part of the United States National
Institutes of Health (NIH), the HPTN works
through an international network of scientists
and investigators in partnership with a leadership group from three US-based institutions.

GCP
Good clinical practice, an international ethical
and scientific quality standard for the design,
conduct, performance, monitoring, auditing,
recording, analysis, and reporting of clinical trials intended to ensure the integrity and validity
of clinical data upon which product approvals
are based and to help protect the rights, safety,
confidentiality, and welfare of human subjects.
HIVNET
HIV Network for Prevention Trials, an international network of clinical trial sites, funded by
the United States National Institutes of Health
(NIH) from 1993–99 for conducting trials
designed to evaluate the safety and efficacy of
promising interventions to prevent sexual, perinatal, and parenteral transmission of HIV infection, using HIV seroincidence as the primary
endpoint. Although they were originally established to focus on HIV vaccines, the interventions evaluated by HIVNET also encompassed
topical microbicides, treatment of sexually
transmitted diseases, prophylaxis to prevent
mother-to-child transmission of infection, and
behavioral risk-reduction strategies.

ICH
The International Committee on Harmonisation
of Technical Requirements for Registration of
Pharmaceuticals for Human Use, a project that
brings together the regulatory authorities of
Europe, Japan, and the United States with experts from the pharmaceutical industry to discuss
scientific and technical aspects of product registration. The purpose of the committee is to recommend ways to better interpret and apply technical guidelines and requirements for product
registration in order to reduce duplication of
testing during the development of new medicines
to make economical use of resources, and to
eliminate unnecessary delay in development and
availability of new medicines, while maintaining
regulatory obligations and safeguards on quality,
safety, and efficacy to protect public health.

HIV serodiscordance
A situation in which one partner in a couple is
infected with HIV and the other is uninfected.

IRB
Institutional review board, a board, committee,
or other group formally designated by an insti-

44

IPD.INFORMEDCONSENT.2006

3/28/06

1:32 PM

Page 45

tution to review, approve, and conduct periodic
review of biomedical research involving human
beings. An IRB’s membership should reflect a
diversity of scientific and nonscientific capacities and disciplines. In accordance with the US
Food and Drug Administration’s and US Office
of Human Research Protections regulations, an
IRB reviews research protocols and related
materials (for example, informed consent documents and investigator brochures) and has the
authority to approve, require modifications to
(to secure approval), or disapprove research.
The primary purpose of such review is to assure
the protection of the rights and welfare of
human participants in research.

MDP
The Microbicides Development Programme, a
partnership formed to develop vaginal microbicides for the prevention of HIV transmission.
The MDP is funded by the UK Department
for International Development (DFID) and
administered by the Medical Research Council
Clinical Trials Unit and Imperial College,
London. It brings together academic institutions in the North and South, nonprofit organizations, and pharmaceutical companies.
Mechanism of action
The way a drug works or produces its biological
effect.

Key informant(s)
Local individual(s) who can provide important
information about the community and help
researchers understand the study population
and cultural environment. They are knowledgeable, observant, and articulate and often have
special knowledge or understanding on topics
of special interest. Key informants can help
researchers understand phenomena that may
not be obvious to an outsider.

Medline
An electronic/online database for scientific publications operated by the National Library of
Medicine (NLM), part of the US government’s
National Institutes of Health.
Microbicides
A range of products, potentially in gel, cream,
film, or suppository form, being developed to
prevent the transmission of HIV and other
sexually transmitted infections when applied
topically.

Longitudinal study
A study designed to follow subjects forward
through time.

MIRA
Methods of Improving Reproductive Health in
Africa; a multisite randomized controlled trial
being conducted in South Africa and
Zimbabwe to determine the acceptability, feasibility, and effectiveness of the latex diaphragm
used with a lubricant in preventing heterosexual
transmission of HIV and other sexually transmitted infections among women. Combining a
physical barrier that covers the cervix with a
spermicide/microbicide is expected to enhance
protection against transmission of STIs, including HIV, and to prevent pregnancy.

MCC
Medicines Control Council of South Africa,
a statutory body established in the Medicines
and Related Substances Control Act 101 of
1965 to oversee the regulation of medicines
in South Africa. The Council is appointed by
the Minister of Health, and its main purpose
is to safeguard and protect the public by ensuring that all medicines sold and used in South
Africa are safe, therapeutically effective, and
consistently meet acceptable standards of
quality.
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of Phase 1 trials is to determine the metabolic
and pharmacological actions of the drug upon
human subjects and to assess its safety, with the
ultimate goal of obtaining sufficient information
about the drug’s effects to permit the design of
valid Phase 2 studies. Phase 1 trials often
include dosing assessments to determine optimal
or threshold concentrations of the active agent
for safety and potential effectiveness.

Partial effectiveness
A term that refers to estimates of effectiveness of
infection-prevention products ranging from 40
to 70 percent; the effectiveness of initial products such as microbicides and vaccines are
expected to be considerably lower than the effectiveness of condoms used correctly and consistently (98 percent). A product such as a vaccine
or microbicide may be effective only some of the
time or only for some users, or both.

Phase 2 Trials
Phase 2 trials expand initial safety (Phase 1) trials to include a larger number of participants
(no more than several hundred) who are at
higher risk and who more closely approximate
the people who are likely to participate in
future efficacy trials. Phase 2 trials, therefore,
gather data about safety among the potential
users of a product or treatment and help to
determine any short-term side effects or risks
associated with the drug or treatment. In some
cases, Phase 2 trials are also used to establish
appropriate doses of medications or treatments.

Participant advisory group
A group comprised of volunteers who are participants in a research project. Similar to a community advisory board or group, a participant
advisory group is a formal mechanism that
enables research participants to provide feedback to the research team and that is convened
to ensure that participants’ needs for support
and information are addressed.
Partners in Prevention
A study currently being conducted by the University of Washington School of Medicine at
sites in Africa to determine whether suppressing
genital herpes can significantly reduce HIV
transmission. The Phase 3 randomized placebocontrolled trial is being conducted among HIVdiscordant couples and is the first to evaluate
whether transmission of HIV-1 can be reduced
by treating genital herpes with acyclovir, a widely used and generically available medication;
researchers theorize that the treatment could
reduce HIV transmission by 50 percent.

Phase 3 Trials
Also known as efficacy (or effectiveness) trials,
these are clinical trials designed to answer the
question: Does this product or intervention
work? The question can concern treating or
preventing the condition or disease being studied. At this level, the new product or treatment
is administered to a large number of participants (usually several hundred to several thousand) in different clinical settings to determine
its safety and efficacy. When these studies are
completed and the sponsor believes that the
product is safe and effective under specific conditions, the sponsor applies to the Food and
Drug Administration or other national regulatory authority for approval to market the drug.

Phase 1 Trials
Also known as safety trials, Phase 1 clinical trials
are conducted in a small group (generally in the
range of 20–80 individuals) of healthy participants at low risk of infection who are monitored
carefully for any evidence of adverse effects of
the intervention or treatment. Sometimes, where
the drug being investigated is intended for use
among people with a particular disease, patients
with the disease may participate. The objective

Phase 4 Trials
If Phase 3 clinical trials establish adequate safety
and effectiveness or efficacy of an intervention
product, concurrent with marketing approval, the
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immediate direction the test product is administered or dispensed to a study participant). If a
trial is conducted by a team of individuals at a
trial site, the investigator is the responsible leader
of the team and may be called the principal investigator. A sponsor-investigator is an individual
who both initiates and conducts a clinical trial,
alone or with others, and under whose immediate
direction the investigational product is administered or dispensed to a study participant.

regulatory authority may seek agreement from a
sponsor to conduct Phase 4 (postmarketing) studies to gather additional information about safety
(especially with long-term use or in diverse populations), benefits, and optimal use under field
conditions. These studies could include, but would
not be limited to, examining different dosages or
schedules of administration than were tested in
Phase 2 studies, use of the drug in other patient
populations or at other stages of the disease, or
use of the drug over a longer period of time.

Pro-2000
A candidate vaginal microbicide, developed by
Indevus, currently in safety, acceptability, and
efficacy trials. It is an entry-and-fusion inhibitor
(napthalene sulphonate polymer) that binds to
viruses and bacteria to prevent them from binding to and infecting healthy cells. It may protect
against HIV, gonorrhea, and HSV. Its contraceptive efficacy is expected to be dose dependent.

Placebo
An inactive medical treatment—a chemically
inert substance that has no specific pharmacological effect on the illness or condition being
studied—given to participants in the control
group of a clinical trial. Use of a placebo allows
the effects of the experimental treatment given
to the study group to be distinguished and
enables investigators to learn whether it produces results. Use of a placebo can also help
determine whether improvement and/or side
effects may reflect the user’s imagination or
anticipation rather than the power of a drug.

Protocol
An explicit, detailed plan for a study, experiment,
procedure, or test. The protocol defines question(s) to be answered and provides complete,
specific details concerning procedures, selection
of participants, assignment of participants to
treatment groups, adherence, follow-up, and withdrawal. The protocol document describes the
intervention, the activities to be undertaken, the
groups to receive the intervention, and the roles
and responsibilities of the investigators; it should
also spell out the study’s objectives, how the results
will be measured, and the intent of the work.

PREP
Pre-exposure prophylaxis, the use of an antiviral
drug taken prior to HIV exposure for prevention
of HIV transmission. Examples of known effective
uses of PREP are the provision of nevirapine, AZT
(zidovudine, formerly called azidothymidine),
and/or other drugs to prevent mother-to-childtransmission of HIV infection during pregnancy
or childbirth. Clinical trials to evaluate the effectiveness of PREP to prevent sexual or IDU-related
infection are currently underway. Postexposure
prophylaxis (PEP), in which use of antiretroviral
drugs is initiated soon after possible exposure to
HIV, is already employed in many health-care settings, and to prevent HIV infection following rape.

Randomization
Assignment of participants in a trial to treatment groups according to some known probability distribution; a procedure or method for
assigning treatments to participants or dividing
participants into treatment groups by random
allocation. Randomization is generally used to
eliminate selection bias by researchers or participants, to ensure that the statistical analysis of
data will be valid, and to create groups compa-

(Principal) investigator
An individual who actually conducts a clinical
investigation (that is, the individual under whose
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part of combination therapy. Currently, tenofovir is undergoing safety and effectiveness trials
as pre-exposure prophylaxis (see PREP)—a
once-a-day pill that may reduce the likelihood
of acquiring HIV infection.

rable with respect to all factors that could influence outcome.

Savvy (C-31 G)
A candidate vaginal microbicide, developed by
Biosyn, currently in safety and efficacy trials; a
surfactant (detergent) that breaks down the lipid
membranes of enveloped viruses and bacteria.
Savvy is expected to act as a contraceptive and
may protect against HIV, chlamydia, and HSV.

Therapeutic misconception
A trial participant’s distorted understanding of
the benefits and risks of participating in clinical
research, that is, confusion between research and
treatment; a study participant’s belief that he or
she will experience personally a direct therapeutic
benefit from the research. Even after explanation
of the experimental nature of the research, trial
participants may not understand that the test
product could be ineffective and fail to protect
them, and that the placebo offers no protection.
The therapeutic misconception results from participants’ confusing the research setting with the
care setting, such that they believe the researchers
are “treating” them for their health needs.

Standard operating procedures (SOPs)
Standard operating procedures are clearly written descriptions of processes to be followed and
particular tasks to be performed that have been
standardized to ensure that they are followed or
performed the same way each time they are
undertaken. In clinical trials, SOPs are essential
for ensuring that regulatory and organizational
policy requirements are met, for training new
personnel, and for managing workload; they
ensure that the site has consistent processes that
meet or exceed regulatory and good clinical
practice standards, that all employees are familiar with the processes, and that processes are
reviewed and updated on a regular basis.

Vaccine
A biological product that contains an antigen,
generally made from an infectious agent or its
components—a virus, bacterium, or other microorganism—that is killed (inactive) or live-attenuated (active, although weakened). Vaccines may
be biochemically or genetically synthesized. A
vaccine is designed to trigger the immune system to respond to a disease antigen and stimulate the production of antibodies to protect
against the specific disease, and thus confer
immunity against the disease that the organisms
cause, for a period of time or permanently.

Sponsor
An individual, company, institution, or organization that takes responsibility for the initiation,
management, and/or financing of a clinical trial.
Tenofovir
An FDA-approved antiretroviral drug (tenofovir
disoproxil fumarate), marketed under the name
VireadTM, that is now widely used in combination with other antiretrovirals to treat HIV
infection. Tenofovir is a nucleotide analog
reverse transcriptase inhibitor (NRTI); it blocks
the functioning of HIV reverse transcriptase, an
enzyme that HIV requires to multiply in the
human body. Tenofovir is not a cure for HIV,
but it has been shown to reduce the HIV viral
load among many patients when it is used as

Voluntary counseling and testing (VCT)
The process by which an individual undergoes
confidential counseling to enable the individual
to make an informed choice about learning his
or her HIV status and to take appropriate action.
If the individual chooses to take the HIV test,
VCT enables confidential testing. The voluntary
nature of VCT is one of its underlying principles.
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Appendix 1: Workshop Agenda
Workshop on Informed Consent in HIV Prevention Trials
Cohosted by the Population Council and Family Health International
Population Council, New York, NY
16–18 May 2005

Agenda
Monday, 16 May
8:30–9:00

Continental Breakfast and Registration

9:00–9:15

Welcome

Peter Donaldson
President, Population Council

9:15–9:30

Review of the Agenda and Workshop Goals

Barbara Friedland
Population Council

9:30–10:45

Setting the Stage

Moderator: Johannes van Dam
Population Council

An Overview of the Challenges Implicit in
Facilitating Informed Decisionmaking among
Research Participants in the Developing
World (20 minutes)

Jerome Singh
Center for the AIDS Programme
of Research in South Africa

Informed Consent in Context (20 minutes)

Kathleen MacQueen
Family Health International

Informed Consent Challenges: Institutional
Requirements (20 minutes)

Barbara Pennington
Pharmaceutical Product Development

Discussion (15 minutes)
10:45–11:00

Break

11:00–12:30

Current Informed Consent Processes and
Procedures

Moderator/Discussant: Nancy Kass
Johns Hopkins University

Informed Consent for HPTN 035 (20 minutes)

Cynthia Woodsong
Research Triangle Institute

Informed Consent Process: The Botswana
Oral Tenofovir Prophylaxis Trial (20 minutes)

Kata Chillag
US Centers for Disease Control and
Prevention

HSV-2/HIV Transmission Study: Recruitment
and Informed Consent Issues with HIVdiscordant Couples (20 minutes)

Andrew Mujugira
University of Washington,
Partners in Prevention

Discussion (30 minutes)
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Lunch
During lunch, those who are interested can view
the Carraguard Phase 3 video and the MIRA trial
video, which will be discussed tomorrow morning.

1:30–3:45

Factors Influencing Decisionmaking

Moderator: Martha Brady
Population Council

Risk Perception and Decisionmaking
(20 minutes)

Julie Downs
Carnegie Mellon University

The Impact of Participant Remuneration on
Informed Consent (15 minutes)

Keymanthri Moodley
University of Stellenbosch

Community Influence on Informed Consent
(10 minutes)

Marge Chigwanda
UZ/UCSF Collaborative Research
Programme

The Informed Consent Advocate (10 minutes)

John Attafuah
Visual Access, LTD

Discussion (25 minutes)
3:45–4:00

Break

4:00–5:00

Men in Microbicides Trials

Moderator: Lori Heise
Global Campaign for Microbicides

Male Partner Consent for Microbicide Trials
(10 minutes)

Neelam Jogklekar
National AIDS Research Institute

Male Involvement in Microbicide Trials
(10 minutes)

Sicelo Gumede
Medical Research Council, South Africa

Men in Microbicide Trials: Carraguard Couples
Study (10 minutes)

Supaporn Chaikummao
Thai Ministry of Public Health/US Centers
for Disease Control and Prevention
Collaboration

Discussion (30 minutes)
5:00–7:00

Reception
There will be a reception for meeting participants
and Population Council colleagues on the
eighth floor.
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Tuesday, 17 May
8:30–9:00

Continental Breakfast

9:00–10:15

Challenges in the Development and Implementation of the Informed Consent Process

Moderator: Barbara Friedland
Population Council

IEC and the Informed Consent Process
(20 minutes)

Maggie Díaz
Reprolatina – Soluções Inovadoras
em Saúde Reprodutiva

The Costs of Informed Consent (20 minutes)

John Townsend
Population Council

Discussion (20 minutes)
10:15–10:30

Break

10:30–12:00

Three Case Studies on Materials
Development

Moderator: Barbara Friedland
Population Council

Carraguard Phase 3 Trial: Developing and
Implementing a Video (20 minutes)

Alana de Kock
University of Cape Town
Mabitso Marumo
University of Limpopo, Medunsa

Challenges in the Development and
Implementation of the Informed Consent
Process: The MIRA Study (20 minutes)

Sinazo Pato
Perinatal HIV Research Unit,
Baragwanath Hospital

AIDSVax Phase 3 Trial (20 minutes)

Punnee Pitisuttithum
Mahidol University

Discussion (30 minutes)
12:00–1:00

Lunch
During lunch, those who are interested can
view the Partners in Prevention video –
a work-in-progress being developed for
the HSV-2/HIV Couples study.

1:00–2:30

Assessing Comprehension

Moderator: Kathleen MacQueen
Family Health International

Checking for Levels of Competence
(20 minutes)

Elva Moser
Swift Consulting and Coaching Consortium

Three Case Studies on Assessing
Comprehension
Comprehension in a Microbicide Feasibility
Study (15 minutes)

Neetha Morar
Medical Research Council, South Africa

HPTN 035 Informed Consent Comprehension
Assessment (15 minutes)

Anne Coletti
Family Health International

Assessing Comprehension of the Informed
Consent in a Phase 3 Trial of Cellulose
Sulfate (15 minutes)

Lut Van Damme
CONRAD

Discussion (20 minutes)
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2:30–2:45

Break

2:45–4:00

Monitoring and Evaluating the Informed
Consent Process

Moderator: Jeremy Sugarman
Johns Hopkins University

Empirical Evidence on Improving Research
Participants’ Understanding (15 minutes)

James Flory
University of Pennsylvania

In-depth Interviews to Evaluate the Informed
Consent Process (15 minutes)

Agnes Ssali
Medical Research Council Programme
on AIDS in Uganda/Uganda Virus
Research Initiative

Informed Consent: What Should We Be
Evaluating and Why? (20 minutes)

Jeremy Sugarman
Johns Hopkins University

Discussion (25 minutes)
4:00–4:45

Summary and conclusion

Elizabeth McGrory
Population Council Consultant

4:45–5:00

Closing remarks

Barbara Friedland
Population Council

5:00

Meeting adjourns

Wednesday, 18 May
8:30–9:00

Continental Breakfast

9:00–10:30

Learning about Learning

10:30–10:45

Break

10:45–1:00

Communicating Complex Concepts

1:00–1:45

Lunch

1:45–2:45

Training Staff for Informed Consent Activities

Speaker/Moderator: Cynthia Woodsong
Research Triangle Institute

2:45–3:00

Closing remarks

Barbara Friedland
Population Council

3:00

Meeting adjourns

Speaker/Moderator: Elva Moser
Swift Consulting and Coaching
Consortium
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Appendix 2: List of Participants
Arthur Allen
Quality Assurance Unit Manager
Population Council
Center for Biomedical Research
1230 York Avenue
New York, NY 10021, USA
Tel: (212) 327-7188
Fax: (212) 327-7678
E-mail: aallen@popcouncil.org

Kelly Blanchard
President
Ibis Reproductive Health
2 Brattle Square
Cambridge, MA 02138–3742, USA
Tel: (617) 349-0040
Fax: (617) 349-0041
E-mail: kblanchard@ibisreproductivehealth.org

Sandra Arnold
Vice President, Corporate Affairs
Population Council
One Dag Hammarskjold Plaza
New York, NY 10017, USA
Tel: (212) 339-0663
Fax: (212) 755-6052
E-mail: sarnold@popcouncil.org

Hillary Bracken
Consultant
c/o Population Council
One Dag Hammarskjold Plaza
New York, NY 10017, USA
Tel: (212) 339-0500
Fax: (212) 755-6052
E-mail: hbracken@gynuity.com

John Attafuah
Chief Executive Officer
Virtual Access, Ltd.
6 Odono Street
North Kaneshie, DTD-ARW
Accra, Ghana
Tel: (233) 21-222-381
Fax: (233) 21-231-415
E-mail: jattafuah@tdftema.org
johnattafuah@4u.com.gh
Judith Auerbach
Vice President
Public Policy and Program
Development
American Foundation for AIDS
Research
1828 L Street, NW, Suite 802
Washington, DC 20036, USA
Tel: (202) 331-8600
Fax: (202) 331-8606
E-mail: judy.auerbach@amfar.org
Julie Becker
Senior Director
Country and Regional Programmes
International AIDS Vaccine Initiative
110 William Street, 27th Floor
New York NY 10038–3901, USA
Tel: (212) 763-5465
Fax: (212) 847-1112
E-mail: jbecker@iavi.org

Martha Brady
Program Associate
Population Council
One Dag Hammarskjold Plaza
New York, NY 10017, USA
Tel: (212) 339-0618
Fax: (212) 755-6052
E-mail: mbrady@popcouncil.org
Patrick Brenny
Country Coordinator
UNAIDS
United Nations Building
12th Floor
Rajadamnem Nok Avenue
Bangkok 10200, Thailand
Tel: (66) 2-288-1882
Fax: (66) 2-280-1414
E-mail: patrick.brenny@un.or.th
Marianne Callahan
Deputy Director/Clinical Director
CONRAD
Eastern Virginia Medical School
1611 North Kent Street,
Suite 806
Arlington, VA 22209, USA
Tel: (703) 524-4744
Fax: (703) 524-4770
E-mail: mcallahan@conrad.org
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Supaporn Chaikummao
Clinical Research Specialist
Thai Ministry of Public Health/
US CDC Collaboration
Department of Disease Control
4th Floor, Building 7
Tivanon Road
Nonthaburi 11000, Thailand
Tel: (66) 2-580-0669, ext. 464
(66) 1-850-4343
Fax: (66) 2-580-0712
E-mail: SupapornC@tuc.or.th
Marge Chigwanda
Counseling Director
UZ-UCSF Collaborative
Research Programme
15 Phillips Avenue
Belgravia
Harare, Zimbabwe
Tel: (263) 4-91-241-699
(263) 4-706-540
Fax: (263) 4-704-897
(263) 4-725-038
E-mail: marge@uz-ucsf.co.zw
Kata Chillag
Behavioral Scientist
HIV Epidemiology Branch
US Centers for Disease Control
and Prevention
1600 Clifton Road, NE, MS E-45
Atlanta, GA 30333, USA
Tel: (404) 639-0948
Fax: (404) 639-6127
E-mail: kchillag@cdc.gov
Anne Coletti
Senior Scientist
Family Health International
HIV Prevention Trials Network
12 Madison Street
Medford, MA 02155, USA
Tel: (781) 874-1208
Fax: (781) 874-1195
E-mail: AColetti@fhi.org
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Paul Coplan
Director of Clinical and
Regulatory Affairs
International Partnership for
Microbicides
1010 Wayne Avenue, Suite 1450
Silver Spring, MD 20910, USA
Tel: (301) 608-2221
Fax: (202) 608-2241
E-mail:
PCoplan@ipm-microbicides.org

Julie Downs
Director
Center for Risk Perception and
Communication
Carnegie Mellon University
Department of Social and
Decision Sciences
Porter Hall 208
Pittsburgh, PA 15213–3890, USA
Tel: (412) 268-6937
E-mail: downs@andrew.cmu.edu

Brittany Dawson
HHS Emerging Leaders Program
National Institute for Child Health
and Human Development
Demographic and Behavioral
Sciences Branch
Executive Building
6100 Executive Boulevard, MSC 7510
Rockville, MD 20892–7510, USA
Tel: (301) 435-6986
Fax: (301) 496-0962
E-mail: brittany.dawson@hhs.gov

Gina Duclayan
Senior Writer/Editor
Population Council
One Dag Hammarskjold Plaza
New York, NY 10017, USA
Tel: (212) 339-0510
Fax: (212) 755-6052
E-mail: gduclayan@popcouncil.org

Alana de Kock
Social Science Investigator
University of Cape Town
School of Public Health and
Family Medicine
Infectious Disease Epidemiology Unit
Falmouth Building
Anzio Road, Observatory 7925
Cape Town, South Africa
Tel: (27) 21-406-6716
Fax: (27) 21-406-6308
E-mail: dekock@cormack.uct.ac.za
Maggie Díaz
Presidenta
Reprolatina - Soluções Inovadoras
em Saúde Sexual Reprodutiva
Rua Maria Teresa Días da Silva
740 Cidade Universitaria
Campinas
São Paolo CEP 13084-190, Brazil
Tel: (55) 19-3289-1735
Fax: (55) 19-3289-1736
E-mail: mdiaz@reprolatina.org.br
Peter Donaldson
President
Population Council
One Dag Hammarskjold Plaza
New York, NY 10017, USA
Tel: (212) 339 0686
Fax: (212) 755-6052
E-mail: pdonaldson@popcouncil.org

Suzie Elliott
Public Information Specialist
Population Council
One Dag Hammarskjold Plaza
New York, NY 10017, USA
Tel: (212) 339-0520
Fax: (212) 755-6052
E-mail: selliott@popcouncil.org
Pat Fast
Director
Medical Affairs, Research and
Development
International AIDS Vaccine Initiative
110 William Street, 27th Floor
New York, NY 10038–3901, USA
Tel: (212) 847-1068
Fax: (212) 847-1112
E-mail: pfast@iavi.org
James Flory
Medical Student
University of Pennsylvania
Medical School
Stemmler Hall, 3450 Hamilton Walk
Mailbox 369
Philadelphia, PA 19104–6087, USA
Tel: (301) 452-4288
E-mail: jflory@mail.med.upenn.edu
Barbara Friedland
Program Manager
Population Council
One Dag Hammarskjold Plaza
New York, NY 10017 USA
Tel: (212) 339-0629
Fax: (212) 755-6052
E-mail: bfriedland@popcouncil.org
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Gregg Gonsalves
Director of Treatment and
Prevention Advocacy
Gay Men’s Health Crisis
119 West 24th Street
New York, NY 10011, USA
Tel: (212) 367-1169
Fax: (212) 367-1235
E-mail: greggg@gmhc.org
Sicelo Gumede
Behavioral Coordinator
HIV Prevention Research Unit
Medical Research Council of
South Africa
123 Jan Hofmeyer Drive
Westville 3630, South Africa
Tel: (27) 31-242-3600
Fax: (27) 31-242-3800
E-mail: Sicelo.Gumede@mrc.ac.za
Lori Heise
Director
Global Campaign for Microbicides
c/o PATH
1800 K Street, NW
Washington, DC 20006, USA
Tel: (202) 454-5028
Fax: (202) 457-1466
E-mail: lheise@path-dc.org
Paul Hewett
Associate
Population Council
One Dag Hammarskjold Plaza
New York, NY 10016, USA
Tel: (212) 339-0683
Fax: (212) 755-6052
E-mail: phewett@popcouncil.org
Anrudh Jain
Vice President
International Programs Division
Population Council
One Dag Hammarskjold Plaza
New York, NY 10017, USA
Tel: (212) 339-0639
Fax: (212) 755-6052
E-mail: ajain@popcouncil.org
Neelam Sanjay Joglekar
Behavioural Scientist
National AIDS Research Institute
73, G-block, MIDC, Bhosari
Pune, Maharashtra 411026, India
Tel: (91) 20-2712-1343
Fax: (91) 20-2712-1071
E-mail: joglekarneelam@yahoo.com
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Vice President
Center for Biomedical Research,
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1230 York Avenue
New York, NY 10021, USA
Tel: (212) 327-8717
Fax: (212) 327-7678
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